Professor Fiona Mulcahy

Professor Fiona Mulcahy

Professor


Publications and Further Research Outputs

  • Murphy, P. Hevey, D., O'Shea, S., Ni Rathaille, N., & Mulcahy, F., Optimism, community attachment and serostatus disclosure among HIV-positive men who have sex with men, AIDS Care, 27, 2015, p431 - 435Journal Article, 2015, DOI
  • Murphy PJ, Hevey D, O'Dea S, Ní Rathaille N, Mulcahy F. , Serostatus Disclosure, Stigma Resistance, and Identity Management Among HIV-Positive Gay Men in Ireland, Qual Health Res, 26, (11), 2016, p1459 - 1472Journal Article, 2016, DOI
  • MACLEOD, D, KANE, B, KIDNEY, D, MURPHY, J, OBRIAIN, DS, JACKSON, F, MULVIHILL, B, MULCAHY, F, CLANCY, L, PRICHARD, JS, A CLINICOPATHOLOGICAL STUDY OF 79 BRONCHOSCOPIES IN HIV-POSITIVE PATIENTS, IRISH MEDICAL JOURNAL, 86, 1993, 167 - 169Miscellaneous, 1993
  • CLARKE, S, MULCAHY, F, BERGIN, C, REYNOLDS, H, BOYLE, N, BARRY, M, BACK, DJ, ABSENCE OF OPIOID WITHDRAWAL SYMPTOMS IN PATIENTS RECEIVING METHADONE AND THE PROTEASE INHIBITOR LOPINAVIR-RITONAVIR, CLINICAL INFECTIOUS DISEASES, 34, 2002, 1143 - 1145Miscellaneous, 2002
  • MOCROFT, A, KATLAMA, C, JOHNSON, AM, PRADIER, C, ANTUNES, F, MULCAHY, F, CHIESI, A, PHILLIPS, AN, KIRK, O, LUNDGREN, JD, EUROSIDA STUDY GRP, AIDS ACROSS EUROPE, 1994-98: THE EUROSIDA STUDY, LANCET, 356, 2000, p291 - 296Journal Article, 2000
  • OREILLY, M, BERGIN, C, MULCAHY, F, AIDS-RELATED MALIGNANCIES IN IRELAND 1987-1994, JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY, 8, 1997, p116 - 120Journal Article, 1997
  • MERRY, C, ALPHA(1)-ACID GLYCOPROTEIN CONCENTRATION IN HIV DISEASE - IMPLICATIONS FOR TREATMENT WITH PROTEASE INHIBITORS, unknown, 1996, 10, ISI Web of Science, 1996, ppP21 - P21Meeting Abstract, 1996
  • BARRY, M, BACK, DJ, ANTIRETROVIRAL THERAPY FOR PATIENTS WITH HIV DISEASE, by MULCAHY, F , BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 45, 1998, p221 - 228Review, 1998
  • LEONARD, N, MCCREARY, C, FLINT, SF, MABRUK, MJEMF, MULCAHY, F, TONER, M, AUTOPSY FINDINGS IN THE TONGUES OF 20 PATIENTS WITH AIDS, JOURNAL OF ORAL PATHOLOGY & MEDICINE, 26, 1997, p244 - 247Journal Article, 1997
  • BARRY, M, AZIDOTHYMIDINE (AZT) AND HEPATIC DRUG-METABOLISM, unknown, 1988, 95, ISI Web of Science, 1988, ppP614 - P614Meeting Abstract, 1988
  • ODONOVAN, ML, FITZPATRICK, F, MULCAHY, F, GAFFNEY, EF, CALCIFYING PNEUMOCYSTIS CARINII THYROIDITIS, INTERNATIONAL JOURNAL OF STD & AIDS, 8, 1997, p652 - 654Journal Article, 1997
  • BOYLE, BM, SULLIVAN, DJ, FORKIN, C, MULCAHY, F, KEANE, CT, COLEMAN, DC, CANDIDA DUBLINIENSIS CANDIDAEMIA IN AN HIV-POSITIVE PATIENT IN IRELAND, INTERNATIONAL JOURNAL OF STD & AIDS, 13, 2002, p55 - 57Journal Article, 2002
  • NI RIAIN, A, STEWART, M, PHELAN, D, BURY, G, MULCAHY, F, CERVICAL SMEARS: COMPARISON OF KNOWLEDGE AND PRACTICE OF A GENERAL PRACTICE SAMPLE WITH A HIGH-RISK GROUP, INTERNATIONAL JOURNAL OF STD & AIDS, 12, 2001, p171 - 175Journal Article, 2001
  • MCCREARY, C, BERGIN, C, PILKINGTON, R, KELLY, G, MULCAHY, F, CLINICAL-PARAMETERS ASSOCIATED WITH RECALCITRANT ORAL CANDIDOSIS IN HIV-INFECTION - A PRELIMINARY-STUDY, INTERNATIONAL JOURNAL OF STD & AIDS, 6, 1995, 204 - 207Miscellaneous, 1995
  • LUNDGREN, JD, PHILLIPS, AN, PEDERSEN, C, CLUMECK, N, GATELL, JM, JOHNSON, AM, LEDERGERBER, B, VELLA, S, NIELSEN, JO, DEWIT, S, SOMMEREIJNS, B, NIELSEN, T, JENSEN, G, SKINHOJ, P, BENTSEN, K, GERSTOFT, J, MELBYE, M, RANKI, A, VALLE, SL, KATLAMA, C, BERLUREAU, P, DIETRICH, M, SCHWANDER, S, GOEBEL, FD, KOSMIDIS, J, STERGIOU, G, GOUZIA, T, PAPADOPOULOS, A, BANHEGYI, D, MULCAHY, F, YUST, I, BENISHAI, Z, BENTWICH, Z, SACKS, T, MAAYAN, S, CHIESI, A, ANCARANI, F, SCALISE, G, BERTAGGIA, A, FRANCAVILLA, E, CALONGHI, G, CARGNEL, A, ARLOTTI, M, CIAMMARUGHI, R, COLOMBA, A, DELALLA, F, FASSIO, P, FERLINI, A, FIACCADORI, F, PASETTI, G, GIANNELLI, F, GRILLONE, W, LAZZARIN, A, MONFORTE, AD, MIGNANI, E, NUNNARI, A, ORTONA, L, PANICHI, G, PAULUZZI, S, PIERSANTELLI, N, RANIERI, S, RICCIARDIELLO, P, ROSCIOLI, B, SORANZO, M, HEMMER, R, DANNER, S, BLOEMKOLK, D, ANTUNES, F, PROENCA, R, GONZALEZLAHOZ, J, MARTINEZBLANCO, L, CLOTET, B, GATELL, J, BUIRA, E, MIRO, J, PEHRSON, P, LUTHY, R, LEDERGERBER, B, OLSSON, K, GLAUSER, M, HIRSCHEL, B, JOHNSON, A, HAWKES, S, PHILLIPS, A, BARTON, S, MORCINEK, J, PINCHING, A, COLEMAN, D, GJPRUP, I, NIELSEN, J, NIEPORT, C, TEGLBJAERG, L, THORNVAL, A, COMPARISON OF LONG-TERM PROGNOSIS OF PATIENTS WITH AIDS TREATED AND NOT TREATED WITH ZIDOVUDINE, JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 271, 1994, p1088 - 1092Journal Article, 1994
  • FLANAGAN, N, KANE, D, SWEENEY, E, MULCAHY, F, BARNES, L, CRUSTED SCARRING PLAQUES ON THE UPPER PART OF THE BACK, ARCHIVES OF DERMATOLOGY, 134, 1998, p366 - +Journal Article, 1998
  • LANDERS, D, BERGIN, C, OLEARY, A, MERRY, C, KEATING, S, MULCAHY, F, DAPSONE INDUCED METHAEMOGLOBINAEMIA, INTERNATIONAL JOURNAL OF STD & AIDS, 7, 1996, p445 - 447Journal Article, 1996
  • BERGIN, CJ, WALLIS, F, OLEARY, A, OREILLY, M, MOLLOY, M, MULCAHY, F, DAY CASE INSERTION OF HICKMAN LINES IN HIV POSITIVE PATIENTS IN A RADIOLOGICAL UNIT, INTERNATIONAL JOURNAL OF STD & AIDS, 7, 1996, 380 - 382Miscellaneous, 1996
  • PEDERSEN, C, DANNER, S, LAZZARIN, A, GLAUSER, MP, WEBER, R, KATLAMA, C, BARTON, SE, LUNDGREN, JD, CLUMECK, N, DEWIT, S, SOMMEREIJNS, B, NIELSEN, JO, NIELSEN, T, JENSEN, G, SKINHOJ, P, BENTSEN, K, GERSTOFT, J, MELBYE, M, RANKI, A, VALLE, SL, BERLUREAU, P, DIETRICH, M, SCHWANDER, S, GOEBEL, FD, KOSMIDIS, J, STERGIOU, G, GOUZIA, T, PAPADOPOULOS, A, BANHEGYI, D, MULCAHY, F, YUST, I, BENISHAI, Z, BENTWICH, Z, SACKS, T, MAAYAN, S, VELLA, S, CHIESI, A, ANCARANI, F, SCALISE, G, BERTAGGIA, A, FRANCAVILLA, E, CALONGHI, G, EMILIA, R, CARGNEL, A, ARLOTTI, M, CIAMMARUGHI, R, RIMINI, I, COLOMBA, A, DELALLA, F, FASSIO, P, FERLINI, A, FIACCADORI, F, PASETTI, G, GIANNELLI, F, GRILLONE, W, MONFORTE, AD, MIGNANI, E, ANDREA, S, NUNNARI, A, ORTONA, L, PANICHI, G, PAULUZZI, S, PIERSANTELLI, N, RANIERI, S, RICCIARDIELLO, P, ROSCIOLI, B, SORANZO, M, HEMMER, R, REISS, P, ANTUNES, F, GONZALEZLAHOZ, J, POLO, R, CLOTET, B, GATELL, J, BUIRA, E, MIRO, J, PEHRSON, P, LUTHY, R, LEDERGERBER, B, OLSSON, C, GLAUSER, M, HIRSCHEL, B, JOHNSON, A, HAWKES, S, PHILLIPS, A, BARTON, S, MORCINEK, J, PINCHING, A, COLEMAN, D, GJORUP, I, NIEPORT, C, TEGLBJAERG, L, THORNVAL, A, EPIDEMIOLOGY OF CRYPTOSPORIDIOSIS AMONG EUROPEAN AIDS PATIENTS, GENITOURINARY MEDICINE, 72, 1996, p128 - 131Journal Article, 1996
  • RING, M, BOLGER, N, ODONNELL, M, MALKIN, A, BERMINGHAM, N, AKPAN, E, MULCAHY, F, TURNER, MJ, GRIFFIN, M, OLEARY, JJ, EVALUATION OF LIQUID-BASED CYTOLOGY IN CERVICAL SCREENING OF HIGH-RISK POPULATIONS: A SPLIT STUDY OF COLPOSCOPY AND GENITO-URINARY MEDICINE POPULATIONS, CYTOPATHOLOGY, 13, 2002, p152 - 159Journal Article, 2002
  • KEATING, JN, TRIMBLE, KC, MULCAHY, F, SCOTT, JM, WEIR, DG, EVIDENCE OF BRAIN METHYLTRANSFERASE INHIBITION AND EARLY BRAIN INVOLVEMENT IN HIV-POSITIVE PATIENTS, LANCET, 337, 1991, p935 - 939Journal Article, 1991
  • LUNDGREN, JD, BARTON, SE, LAZZARIN, A, DANNER, S, GOEBEL, FD, PEHRSON, P, MULCAHY, F, KOSMIDIS, J, PEDERSEN, C, PHILLIPS, AN, CLUMECK, N, DEWIT, S, SOMMEREIJNS, B, NIELSEN, JO, LUNDGREN, J, NIELSEN, T, JENSEN, G, SKINHOJ, P, BENTSEN, K, GERSTOFT, J, MELBYE, M, RANKI, A, VALLE, SL, KATLAMA, C, BERLUREAU, P, DIETRICH, M, SCHWANDER, S, PAPADOPOULOS, A, BANHEGYI, D, YUST, I, BENISHAI, Z, BENTWICH, Z, SACKS, T, MAAYAN, S, VELLA, S, CHIESI, A, ANCARANI, F, SCALISE, G, BERTAGGIA, A, FRANCAVILLA, E, CALONGHI, G, CARGNEL, A, ARLOTTI, M, CIAMMARUGHI, R, COLOMBA, A, DELALLA, F, FASSIO, P, FERLINI, A, FIACCADORI, F, PASETTI, G, GIANNELLI, F, GRILLONE, W, DARMINIO, A, SACCO, L, MIGNANI, E, NUNNARI, A, ORTONA, L, PANICHI, G, PAULUZZI, S, PIERSANTELLI, N, RANIERI, S, RICCIARDIELLO, P, ROSCIOLI, B, SORANZO, M, HEMMER, R, BLOEMKOLK, D, ANTUNES, F, PROENCA, R, GONZALEZLAHOZ, J, MARTINEZBLANCO, L, CLOTET, B, GATELL, J, BUIRA, E, MIRO, J, LUTHY, R, LEDERGERBER, B, OLSSON, C, GLAUSER, M, HIRSCHEL, B, JOHNSON, A, HAWKES, S, PHILLIPS, A, BARTON, S, MORCINEK, J, PINCHING, A, COLEMAN, D, GJORUP, I, NIELSEN, J, NIEPORT, C, TEGLBJAERG, L, THORNVAL, A, FACTORS ASSOCIATED WITH THE DEVELOPMENT OF PNEUMOCYSTIS-CARINII PNEUMONIA IN 5,025 EUROPEAN PATIENTS WITH AIDS, CLINICAL INFECTIOUS DISEASES, 21, 1995, p106 - 113Journal Article, 1995
  • MURPHY, M, MULCAHY, F, FOURNIER GANGRENE AND HIV DISEASE, GENITOURINARY MEDICINE, 69, 1993, 326 - 326Miscellaneous, 1993
  • MCDONNELL, RJ, MCDONNELL, PM, ONEILL, M, MULCAHY, F, HEALTH RISK PROFILE OF PROSTITUTES IN DUBLIN, INTERNATIONAL JOURNAL OF STD & AIDS, 9, 1998, p485 - 488Journal Article, 1998
  • EGAN, JF, OLEARY, B, LEWIS, MJ, MULCAHY, F, SHEEHY, N, HASEGAWA, H, FITZPATRICK, F, OCONNOR, JJ, ORIORDAN, J, HALL, WW, HIGH RATE OF HUMAN T LYMPHOTROPIC VIRUS TYPE IIA INFECTION IN HIV TYPE 1-INFECTED INTRAVENOUS DRUG ABUSERS IN IRELAND, AIDS RESEARCH AND HUMAN RETROVIRUSES, 15, 1999, p699 - 705Journal Article, 1999
  • MULCAHY, F, HIV, AIDS, AND THE BRAIN - ASSOCIATION FOR RESEARCH IN NERVOUS AND MENTAL DISEASE, VOL 72 - PRICE,RW, PERRY,SW, IRISH JOURNAL OF PSYCHOLOGICAL MEDICINE, 11, 1994, 102 - 102Miscellaneous, 1994
  • BALSLEV, U, MONFORTE, AD, STERGIOU, G, ANTUNES, F, MULCAHY, F, PEHRSON, PO, PHILLIPS, A, PEDERSEN, C, LUNDGREN, JD, INFLUENCE OF AGE ON RATES OF NEW AIDS-DEFINING DISEASES AND SURVIVAL IN 6546 AIDS PATIENTS, SCANDINAVIAN JOURNAL OF INFECTIOUS DISEASES, 29, 1997, p337 - 343Journal Article, 1997
  • MERRY, C, BARRY, MG, RYAN, M, TJIA, JF, HENNESSY, M, EAGLING, VA, MULCAHY, F, BACK, DJ, INTERACTION OF SILDENAFIL AND INDINAVIR WHEN CO-ADMINISTERED TO HIV-POSITIVE PATIENTS, AIDS, 13, 1999, pF101 - F107Journal Article, 1999
  • BERGIN, C, PILKINGTON, R, MCCREARY, C, MULCAHY, F, CROWLEY, V, LACTIC-ACIDOSIS, NON-HODGKINS-LYMPHOMA AND THE ACQUIRED-IMMUNODEFICIENCY-SYNDROME, GENITOURINARY MEDICINE, 70, 1994, 148 - 149Miscellaneous, 1994
  • CLARKE, S, HARRINGTON, P, CONDON, C, KELLEHER, D, SMITH, OP, MULCAHY, F, LATE ONSET HEPATITIS AND PROLONGED DETERIORATION IN HEPATIC FUNCTION ASSOCIATED WITH NEVIRAPINE THERAPY, INTERNATIONAL JOURNAL OF STD & AIDS, 11, 2000, p336 - 337Journal Article, 2000
  • MCLOUGHLIN, P, MULCAHY, F, OBRIAIN, DS, KANE, B, MULVIHILL, E, PRICHARD, JS, LUNG PATHOLOGY IN HIV POSITIVE PATIENTS, IRISH MEDICAL JOURNAL, 83, 1990, p109 - 111Journal Article, 1990
  • HUTCHINSON, S, COURTNEY, R, MULCAHY, F, OCONNOR, M, MULLANEY, S, KILBRIDE, R, MONITORING CYTOMEGALOVIRUS RETINITIS PREVALENCE IN AN HIV-SEROPOSITIVE COHORT: THE ASSESSMENT OF IMPROVEMENTS OBSERVED FOLLOWING THE INTRODUCTION OF HIGHLY ACTIVE ANTIRETROVIRAL TRIPLE THERAPY, INTERNATIONAL JOURNAL OF STD & AIDS, 10, 1999, p652 - 656Journal Article, 1999
  • MULCAHY, F, BARRY, M, MERRY, C, BACK, D, NELFINAVIR AND NEVIRAPINE INTERACTION?, AIDS, 12, 1998, 2361 - 2361Miscellaneous, 1998
  • DOWLING, S, MULCAHY, F, GIBNEY, MJ, NUTRITION IN THE MANAGEMENT OF HIV ANTIBODY POSITIVE PATIENTS - A LONGITUDINAL-STUDY OF DIETETIC OUTPATIENT ADVICE, EUROPEAN JOURNAL OF CLINICAL NUTRITION, 44, 1991, p823 - 829Journal Article, 1991
  • SULLIVAN, D, BENNETT, D, HENMAN, M, HARWOOD, P, FLINT, S, MULCAHY, F, SHANLEY, D, COLEMAN, D, OLIGONUCLEOTIDE FINGERPRINTING OF ISOLATES OF CANDIDA SPECIES OTHER THAN CANDIDA-ALBICANS AND OF ATYPICAL CANDIDA SPECIES FROM HUMAN IMMUNODEFICIENCY VIRUS-POSITIVE AND AIDS PATIENTS, JOURNAL OF CLINICAL MICROBIOLOGY, 31, 1993, p2124 - 2133Journal Article, 1993
  • KERR, JR, KANE, D, CROWLEY, B, LEONARD, N, OBRIAIN, S, COYLE, PV, MULCAHY, F, PARVOVIRUS B19 INFECTION IN AIDS PATIENTS, INTERNATIONAL JOURNAL OF STD & AIDS, 8, 1997, p184 - 186Journal Article, 1997
  • BARRY, M, HOWE, JL, ORMESHER, S, BACK, DJ, BRECKENRIDGE, AM, BERGIN, C, MULCAHY, F, BEECHING, N, NYE, F, PHARMACOKINETICS OF ZIDOVUDINE AND DIDEOXYINOSINE ALONE AND IN COMBINATION IN PATIENTS WITH THE ACQUIRED-IMMUNODEFICIENCY-SYNDROME, BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 37, 1994, p421 - 426Journal Article, 1994
  • OCONNOR, WJ, MURPHY, GM, DARBY, C, FOGARTY, J, MULCAHY, F, OMOORE, R, BARNES, L, PORPHYRIN ABNORMALITIES IN ACQUIRED IMMUNODEFICIENCY SYNDROME, ARCHIVES OF DERMATOLOGY, 132, 1997, p1443 - 1447Journal Article, 1997
  • BARRY, M, BACK, D, MULCAHY, F, PROTEASE INHIBITORS IN PATIENTS WITH HIV DISEASE - CLINICALLY IMPORTANT PHARMACOKINETIC CONSIDERATIONS, by GIBBONS, S , CLINICAL PHARMACOKINETICS, 32, 1997, p194 - 209Review, 1997
  • BLAXHULT, A, KIRK, O, PEDERSEN, C, DIETRICH, M, BARTON, SE, GATELL, JM, MULCAHY, F, HIRSCHEL, B, MOCROFT, A, LUNDGREN, JD, AIDS EUROPE STUDY GRP, REGIONAL DIFFERENCES IN PRESENTATION OF AIDS IN EUROPE, EPIDEMIOLOGY AND INFECTION, 125, 2000, p143 - 151Journal Article, 2000
  • MULCAHY, F, RISK OF AIDS TO HEALTH-CARE WORKERS - REPLY, IRISH MEDICAL JOURNAL, 80, 1987, 296 - 296Miscellaneous, 1987
  • MERRY, C, BARRY, MG, MULCAHY, F, TJIA, JF, HALIFAX, KL, HEAVEY, J, KELLY, C, BACK, DJ, RITONAVIR PHARMACOKINETICS ALONE AND IN COMBINATION WITH SAQUINAVIR IN HIV-INFECTED PATIENTS, AIDS, 12, 1998, 325 - 327Miscellaneous, 1998
  • MERRY, C, MULCAHY, F, BARRY, M, GIBBONS, S, BACK, D, SAQUINAVIR INTERACTION WITH MIDAZOLAM: PHARMACOKINETIC CONSIDERATIONS WHEN PRESCRIBING PROTEASE INHIBITORS FOR PATIENTS WITH HIV DISEASE, AIDS, 11, 1997, 268 - 269Miscellaneous, 1997
  • MERRY, C, BARRY, MG, MULCAHY, F, HALIFAX, KL, BACK, DJ, SAQUINAVIR PHARMACOKINETICS ALONE AND IN COMBINATION WITH NELFINAVIR IN HIV-INFECTED PATIENTS, AIDS, 11, 1997, pF117 - F120Journal Article, 1997
  • MERRY, C, BARRY, MG, MULCAHY, F, RYAN, M, HEAVEY, J, TJIA, JF, GIBBONS, SE, BRECKENRIDGE, AM, BACK, DJ, SAQUINAVIR PHARMACOKINETICS ALONE AND IN COMBINATION WITH RITONAVIR IN HIV-INFECTED PATIENTS, AIDS, 11, 1997, pF29 - F33Journal Article, 1997
  • MERRY, C, SAQUINAVIR PHARMACOKINETICS ALONE AND IN COMBINATION WITH RITONAVIR IN PATIENTS WITH HIV DISEASE., unknown, 1996, 10, ISI Web of Science, 1996, ppOP61 - OP61Meeting Abstract, 1996
  • ORMOND, P, MULCAHY, F, SEXUALLY TRANSMITTED DISEASES IN HIV-POSITIVE PATIENTS, DERMATOLOGIC CLINICS, 16, 1998, p853 - +Journal Article, 1998
  • BERGIN, C, OREILLY, M, GOH, J, ONEILL, D, MULCAHY, F, SEXUALLY TRANSMITTED DISEASES IN THE ELDERLY? A REALITY - REPLY, JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY, 8, 1997, 73 - 73Miscellaneous, 1997
  • HENNESSY, M, KELLEHER, D, SPIERS, JP, BARRY, M, KAVANAGH, P, BACK, D, MULCAHY, F, FEELY, J, ST JOHN'S WORT INCREASES EXPRESSION OF P-GLYCOPROTEIN: IMPLICATIONS FOR DRUG INTERACTIONS, BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 53, 2002, p75 - 82Journal Article, 2002
  • CHARTHAIGH, MN, CROWLEY, B, LYNCH, M, MULCAHY, F, SUCCESSFUL TREATMENT OF CUTANEOUS CYTOMEGALOVIRUS, INTERNATIONAL JOURNAL OF STD & AIDS, 4, 1993, p52 - 53Journal Article, 1993
  • MERRY, C, MCMAHON, C, RYAN, M, OSHEA, E, MULCAHY, F, SMITH, OP, SUCCESSFUL USE OF PROTEASE INHIBITORS IN HIV-INFECTED HAEMOPHILIA PATIENTS, BRITISH JOURNAL OF HAEMATOLOGY, 101, 1998, p475 - 479Journal Article, 1998
  • LUNDGREN, JD, PEDERSEN, C, CLUMECK, N, GATELL, JM, JOHNSON, AM, LEDERGERBER, B, VELLA, S, PHILLIPS, A, NIELSEN, JO, DEWIT, S, SOMMEREIJNS, B, NIELSEN, T, JENSEN, G, SKINHOJ, P, BENTSEN, K, GERSTOFT, J, MELBYE, M, RANKI, A, VALLE, SL, KATLAMA, C, BERLUREAU, P, DIETRICH, M, SCHWANDER, S, GOEBEL, FD, KOSMIDIS, J, STERGIOU, G, GOUZIA, T, PAPADOPOULOS, A, BANHEGYI, D, MULCAHY, F, YUST, I, BENISHAI, Z, BENTWICH, Z, SACKS, T, MAAYAN, S, CHIESI, A, ANCARANI, F, SCALISE, G, BERTAGGIA, A, FRANCAVILLA, E, CALONGHI, G, CARGNEL, A, ARLOTTI, M, CIAMMARUGHI, R, COLOMBA, A, DELALLA, F, FASSIO, P, FERLINI, A, FIACCADORI, F, PASETTI, G, GIANNELLI, F, GRILLONE, W, LAZZARIN, A, MONFORTE, AD, MIGNANI, E, NUNNARI, A, ORTONA, L, PANICHI, G, PAULUZZI, S, PIERSANTELLI, N, RANIERI, S, RICCIARDIELLO, P, ROSCIOLI, B, SORANZO, M, HEMMER, R, DANNER, S, ANTUNES, F, PROENCA, R, GONZALEZLAHOZ, J, MARTINEZBLANCO, L, CLOTET, B, BUIRA, E, MIRO, J, PEHRSON, P, LUTHY, R, OLSSON, C, GLAUSER, M, HIRSCHEL, B, HAWKES, S, BARTON, S, MORCINEK, J, PINCHING, A, COLEMAN, D, SURVIVAL DIFFERENCES IN EUROPEAN PATIENTS WITH AIDS, 1979-89, BRITISH MEDICAL JOURNAL, 308, 1994, p1068 - 1073Journal Article, 1994
  • BARRY, M, THE EFFECT OF AZIDOTHYMIDINE (AZT) ON OXIDATIVE DRUG-METABOLISM IN PATIENTS WITH AIDS, unknown, 1989, 27, ISI Web of Science, 1989, ppP667 - P668Meeting Abstract, 1989
  • CLARKE, SM, MULCAHY, F, HEALY, CM, CONDON, S, BUTLER, KM, THE EFFICACY AND TOLERABILITY OF COMBINATION ANTIRETROVIRAL THERAPY IN PREGNANCY: INFANT AND MATERNAL OUTCOME, INTERNATIONAL JOURNAL OF STD & AIDS, 11, 2000, p220 - 223Journal Article, 2000
  • OBRIAIN, DS, JACKSON, F, COURTNEY, MG, OMALLEY, F, MCDONALD, GS, MULVIHILL, EM, DINN, JJ, TEMPERLEY, IJ, MULCAHY, F, THE EMERGING AIDS EPIDEMIC IN IRELAND - CLINICOPATHOLOGICAL FINDINGS IN 23 EARLY CASES, IRISH MEDICAL JOURNAL, 83, 1990, p50 - 53Journal Article, 1990
  • HOPKINS, S, LYONS, F, MULCAHY, F, BERGIN, C, THE GREAT PRETENDER RETURNS TO DUBLIN, IRELAND, SEXUALLY TRANSMITTED INFECTIONS, 77, 2001, p316 - 318Journal Article, 2001
  • KANE, D, KEATING, S, MCCANN, S, MULCAHY, F, THE MANAGEMENT OF ACUTE MYELOID LEUKAEMIA (AML) IN HUMAN IMMUNODEFICIENCY VIRUS (HIV) INFECTION: A CASE REPORT AND REVIEW, INTERNATIONAL JOURNAL OF STD & AIDS, 8, 1997, p272 - 274Journal Article, 1997
  • BROWN, AJL, LOBIDEL, D, WADE, CM, REBUS, S, PHILLIPS, AN, BRETTLE, RP, FRANCE, AJ, LEEN, CS, MCMENAMIN, J, MCMILLAN, A, MAW, RD, MULCAHY, F, ROBERTSON, JR, SANKAR, KN, SCOTT, G, WYLD, R, PEUTHERER, JF, THE MOLECULAR EPIDEMIOLOGY OF HUMAN IMMUNODEFICIENCY VIRUS TYPE 1 IN SIX CITIES IN BRITAIN AND IRELAND, VIROLOGY, 235, 1997, p166 - 177Journal Article, 1997
  • MULCAHY, F, KELLY, G, TYNAN, M, THE NATURAL-HISTORY OF HIV-INFECTION IN WOMEN ATTENDING A SEXUALLY-TRANSMITTED DISEASE CLINIC IN DUBLIN, GENITOURINARY MEDICINE, 70, 1994, p81 - 83Journal Article, 1994
  • MERRY, C, BARRY, MG, MULCAHY, F, RYAN, M, TJIA, JF, HALIFAX, KL, BRECKENRIDGE, AM, BACK, DJ, THE PHARMACOKINETICS OF COMBINATION THERAPY WITH NELFINAVIR PLUS NEVIRAPINE, AIDS, 12, 1998, p1163 - 1167Journal Article, 1998
  • HEALY, E, MEENAN, J, MULCAHY, F, BARNES, L, THE SPECTRUM OF HIV-RELATED SKIN DISEASES IN AN IRISH POPULATION, IRISH MEDICAL JOURNAL, 86, 1993, p188 - 190Journal Article, 1993
  • CLARKE, S, HARRINGTON, P, BARRY, M, MULCAHY, F, THE TOLERABILITY OF EFAVIRENZ AFTER NEVIRAPINE-RELATED ADVERSE EVENTS, CLINICAL INFECTIOUS DISEASES, 31, 2000, p806 - 807Journal Article, 2000
  • MERRY, C, TOLERABILITY OF RITONAVIR AND SAQUINAVIR DURING TRIPLE THERAPY FOR HIV INFECTION, unknown, 1996, 10, ISI Web of Science, 1996, ppP22 - P22Meeting Abstract, 1996
  • MULCAHY, F, MARSHALL, EJ, BAKSHI, M, MCMAHON, B, WALSH, M, TORSADE-DE-POINTES - 2 CASE-REPORTS, IRISH JOURNAL OF MEDICAL SCIENCE, 151, 1983, 393 - 394Miscellaneous, 1983
  • MURPHY, DJ, MULCAHY, F, TRANSMISSION OF HIV, LANCET, 345, 1995, 988 - 988Miscellaneous, 1995
  • BERGIN, C, OLEARY, A, MCCREARY, C, SABRA, K, MULCAHY, F, TREATMENT OF KAPOSIS-SARCOMA WITH LIPOSOMAL DOXORUBICIN, AMERICAN JOURNAL OF HEALTH-SYSTEM PHARMACY, 52, 1995, p2001 - 2004Journal Article, 1995
  • LYONS, DJ, OMAHONEY, P, KEATING, J, MULCAHY, F, CLANCY, L, TUBERCULIN SKIN TESTING AND THE DEVELOPMENT OF TUBERCULOSIS IN A COHORT OF HIV-INFECTED INDIVIDUALS, IRISH MEDICAL JOURNAL, 87, 1995, p108 - 110Journal Article, 1995
  • CLARKE, S, MULCAHY, F, USE OF ANTIRETROVIRAL AGENTS IN THE TREATMENT OF HIV INFECTION, 1998, -Miscellaneous, 1998
  • BARRY, MG, MERRY, C, LLOYD, J, HALIFAX, K, CAREY, P, MULCAHY, F, BACK, DJ, VARIABILITY IN TROUGH PLASMA SAQUINAVIR CONCENTRATIONS IN HIV PATIENTS - A CASE FOR THERAPEUTIC DRUG MONITORING, BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 45, 1998, 501 - 502Miscellaneous, 1998
  • DOWLING, S, LAMBE, J, MULCAHY, F, VITAMIN-B12 AND FOLATE STATUS IN HUMAN-IMMUNODEFICIENCY-VIRUS INFECTION, EUROPEAN JOURNAL OF CLINICAL NUTRITION, 47, 1993, p803 - 807Journal Article, 1993
  • TRIMBLE, KC, GOGGINS, MG, MOLLOY, AM, MULCAHY, F, SCOTT, JM, WEIR, DG, VITAMIN-B12 DEFICIENCY IS NOT A CAUSE OF HIV-ASSOCIATED NEUROPATHY, AIDS, 7, 1993, 1132 - 1133Miscellaneous, 1993
  • MURPHY, D, LYNCH, M, MULCAHY, F, ZIDOVUDINE RELATED ARTHROPATHY, BRITISH MEDICAL JOURNAL, 309, 1994, 97 - 97Miscellaneous, 1994
  • Lyons F, Prendiville W, Mulcahy F., Cervical Disease in HIV 1 positive women: a review, Intl J Std & AIDS, 15, 2004, p89 - 93Journal Article, 2004
  • Lukhart S, Godornes C, Moline B, Sonnett P, Hopkins S, Engleman J, Mitchell SJ Rompalo A, Marra C, Klausner J, Mulcahy F., Marolide resistance in treponema pallidum in the United States and Ireland, N England J Med, 351, (2), 2004, p154 - 158Journal Article, 2004
  • Ryan M, Merry C, Ryan C, Bennett K, Heerey A, McGowan B, Mulcahy F, Barry M., Population based study of the cost of inpatient care for HIV infected individuals in an Irish teaching hospital, IMJ, 97, (7), 2004, p200 - 202Journal Article, 2004
  • S Hopkins, C Coleman, M Kelleher, S Keating, S Clarke, B O'Connell, F Mulcahy, C Bergin, Increasing resistance to Ciprofloxacin among isolates of Neiserria Gonorrhoea in Dublin, IMJ, 98, (1), 2005, p208 - 208Journal Article, 2005
  • EuroSida Study Group. (includes Mulcahy F), Changes in hospital admission across Europe: 1995 - 2003, HIV Medicine, 5, 2004, p437 - 447Journal Article, 2004
  • d'Arminio Monforte A, Cinque P, Mocroft A, Goebel FD, Antunes F, Katlama C, Justesen US, Vella S, Kirk O, Lundgren J; EuroSIDA Study Group. (includes Mulcahy F), Changing incidence of central nervous system diseases in the EuroSIDA cohort, Ann Neurol., 55, (3), 2004, p320 - 328Journal Article, 2004
  • Fontas E, van Leth F, Sabin CA, Friis-Moller N, Rickenbach M, d'Arminio Monforte A, Kirk O, Dupon M, Morfeldt L, Mateu S, Petoumenos K, El-Sadr W, de Wit S, Lundgren JD, Pradier C, Reiss P; D:A:D Study Group (includes Mulcahy F), Lipid profiles in HIV-infected patients receiving combination antiretroviral therapy: are different antiretroviral drugs associated with different lipid profiles?, J Infect Dis., 189, (6), 2004, p1056 - 1074Journal Article, 2004
  • Mocroft A, Kirk O, Clumeck N, Gargalianos P, Trocha H, Chentsova N, Antunes F, Stellbrink H-J, Phillips AN, Lundgren JD for the EuroSIDA study group. (includes Mulcahy F), The Changing pattern of Kaposi"s sarcoma in patients with HIV - 1994-2003. The EuroSIDA Study, Cancer, 100, 2004, p2644 - 2654Journal Article, 2004
  • Dragsted UB, Mocroft A, Vella S, Viard JP, Hansen AE, Panos G, Mercey D, Machala L, Horban A, and Lundgren JD; EuroSIDA study group. (includes Mulcahy F), Predictors of immunological failure after initial response to HAART in HIV-1 infected adults: a EuroSIDA study, J Infect Dis., 190, (1), 2004, p148 - 155Journal Article, 2004
  • Ledergerber B, Lundgren JD, Walker AS, Sabin C, Justice A, Reiss P, Mussini C, Wit F, d'Arminio Monforte A, Weber R, Fusco G, Staszewski S, Law M, Hogg R, Lampe F, Gill MJ, Castelli F, Phillips AN; PLATO Collaboration. (includes Mulcahy F), Predictors of trend in CD4-positive T-cell count and mortality among HIV-1-infected individuals with virological failure to all three antiretroviral-drug classes, Lancet, 364, (9428), 2004, p51 - 62Journal Article, 2004
  • Kirk O, Mocroft A and Lundgren JD for the EuroSIDA study. (includes Mulcahy F), Reduction af aids og dødsrater i EuroSIDA-studiet. Et observationsstudie, Ugeskrift Laeger, 166, (26-31), 2004, p2571 - 2576Journal Article, 2004
  • Yust I, Fox Z, Burke M, Johnson AM, Tuner D, Mocroft A, Katlama C, Ledergerber B, Reiss P, Kirk O, for the EuroSIDA study. (includes Mulcahy F), Retinal and extraocular cytomegalovirus end-organ disease in HIV-infected patients in Europe. A EuroSIDA study, 1994-2000, Eur J Clin Microbiol Infect Dis., 23, (7), 2004, p550 - 559Journal Article, 2004
  • Cabrera C, Cozzi-Lepri A, Phillips AN, Loveday C, Kirk O, Ait-Khaled M, Reiss P, Kjær J, Ledergerber B, Lundgren JD, Clotet B, Ruiz L; EuroSIDA study group. (includes Mulcahy F), Baseline Resistance and Virologic Outcome in Patients with Virologic Failure who start a Regimen Containing Abacavir: EuroSIDA Study, Antivir Ther., 9, (5), 2004, p787 - 800Journal Article, 2004
  • Phillips AN, Ledergerber B, Horban A, Reiss P, Chiesi A, Kirk O, Mulcahy F, Fisher M, Machala L, Lundgren JD; EuroSIDA Study Group. (includes Mulcahy F), Rate of viral rebound according to specific drugs in the regimen in 2120 patients with HIV suppression, AIDS, 18, (13), 2004, p1795 - 1804Journal Article, 2004
  • d'Arminio A, Sabin CA, Phillips AN, Reiss P, Weber R, Kirk O, El-Sadr W, De Wit S, Mateu S, Petoumenos K, Dabis F, Pradier C, Morfeldt L, Lundgren JD, Friis-Moller N; Writing Committee of the D:A:D: Study Group. (includes Mulcahy F), Cardio- and Cerebrovascular Events in HIV-Infected Persons, AIDS, 18, (13), 2004, p1811 - 1817Journal Article, 2004
  • Mocroft A, d'Arminio Monforte A, Kirk O, Johnson M, Friis-Moller N,, Changes in hospital admissions across Europe:1994-2003. Results from the EuroSIDA study, HIV Med., 5, (6), 2004, p437 - 447Journal Article, 2004
  • Mocroft A, Ledergerber B, Viard JP, Staszewski S, Murphy M, Chiesi A, Horban A, Hansen AB, Phillips AN, Lundgren JD; EuroSIDA Study Group. (includes Mulcahy F), Time to virological failure of 3 classes of antiretrovirals after initiation of highly active antiretroviral therapy: results from the EuroSIDA study group, J Infect Dis., 190, (11), 2004, p1947 - 1956Journal Article, 2004
  • Mocroft A, Gatell J, Reiss P, Ledergerber B, Kirk O, Vella S, Blaxhult A, Phillips AN, Lundgren J; for the EuroSIDA study group. (includes Mulcahy F), Causes of death in HIV infection:the key determinant to define the clinical response to anti-HIV therapy, AIDS, 18, (17), 2004, p2333 - 2337Journal Article, 2004
  • Phillips AN, Ledergerber B, Lundgren JD, Hogg B, d'Arminio Monforte A, Castelli f, Walker S, Staszewski S, Thiébaut R, Gazzard B, Saag M, Petoumenos K, Johnson M, Scullard G, Gill J, James I, Fisher M, Mussini C, Klein M, Costagliola D. (includes Mulcahy F), Nucleoside analogue use before and during highly active antiretroviral therapy and virus load rebound. Collaboration of HIV Cohorts, writting committee, J Infect Dis., 190, 2004, p675 - 687Journal Article, 2004
  • D Konopnicki, A Mocroft, S De Wit, F Antunes, B Ledergerber, C Katlama, K Zilmer, S Vella, O Kirk, and JD Lundgren for the EuroSIDA Group. (includes Mulcahy F), Hepatitis B and HIV: prevalence, AIDS progression, response to HAART and increased mortality in the EuroSIDA cohort, AIDS, 19, (6), 2005, p593 - 601Journal Article, 2005
  • Holkmann Olsen C, Gatell J, Ledergerber B, Katlama C, Friis-Møller N, Weber J, Horban A, Staszewski S, Lundgren J, Phillips A. (includes Mulcahy F), Risk of AIDS and death at given HIV-RNA and CD4 count levels, according to specific antiretroviral drugs in the regimen, AIDS, 19, 2005, p319 - 330Journal Article, 2005
  • A Mocroft, C Oancea, J van Lunzen, P Vanhems, D Banhegyi, A Chiesi, E Vinogradova, S Maayan, AN Phillips and J Lundgren. (includes Mulcahy F), Decline in oesophageal candidiasis and use of antimycotics in patients with HIV, Am J Gastroenterol., 100, (7), 2005, p1446 - 1454Journal Article, 2005
  • A Mocroft, AN. Phillips, V Soriano, J Rockstroh, A Blaxhult, C Katlama, A Boron-Kaczmarska, L Viksna, O Kirk, JD Lundgren (includes Mulcahy F), Reasons for Stopping Antiretrovirals Used in an Initial Highly Active Antiretroviral Regimen: Increased Incidence of Stopping due to Toxicity or Patient/Physician Choice in Patients with Hepatitis C Coinfection, AIDS Res Hum Retroviruses, 21, (9), 2005, p743 - 752Journal Article, 2005
  • J Rockstroh, A Mocroft, V Soriano, C Tural, M Losso, A Horban, O Kirk, A Phillips, B Ledergerber, J Lundgren for the EuroSIDA study group. (includes Mulcahy F), Influence of Hepatitis C o¬n HIV Disease Progression and Response to Antiretroviral Therapy, J Infect Dis., 192, (6), 2005, p992 - 1002Journal Article, 2005
  • A Mocroft, V Soriano, J Rockstroh, P Reiss, O Kirk, S de Wit, J Gatell, B Clotet, AN Phillips, JD Lundgren for the EuroSIDA study group. (includes Mulcahy F), Is there evidence for an increase in the death-rate from liver-related disease in patients with HIV?, AIDS, 19, (18), 2005, p2117 - 2125Journal Article, 2005
  • A Mocroft, J Rockstroh, V Soriano, B Ledergerber, O Kirk, E Vinogradova, P Reiss, C Katlama, AN Phillips, JD Lundgren for the EuroSIDA study group. (includes Mulcahy F), Are specific antiretrovirals associated with an increased risk of discontinuation due to toxicities or patient/physician choice in patients with hepatitis C virus coinfection?, Antivir. Ther., 10, (7), 2005, p779 - 790Journal Article, 2005
  • R Thiebaut, WM El-Sadr, N Friis-Moller, M Rickenbach, P Reiss, AD Monforte, L Morfeldt, E Fontas, O Kirk, S De Wit, G Calvo, MG Law, F Dabis, CA Sabin, JD Lundgren; Data Collection of Adverse events of anti-HIV Drugs Study Group. (includes Mulcahy F), Predictors of hypertension and changes of blood pressure in HIV-infected patients, Antivir Ther., 10, (7), 2005, p811 - 823Journal Article, 2005
  • E Girardi, CA Sabin, A d'Arminio Monforte, B Hogg, AN Phillips, MJ Gill, F Dabis, P Reiss, O Kirk, E Bernasconi, S Grabar, A Justice, S Staszewski, G Fatkenheuer, JA Sterne; Antiretroviral Therapy Cohort Collaboration. (includes Mulcahy F), Incidence of Tuberculosis among HIV-infected patients receiving highly active antiretroviral therapy in Europe and North America, Clin Infect Dis., 41, (12), 2005, p1772 - 1782Journal Article, 2005
  • Clarke S, Delamere S, McCullagh L, Hoskins S, Bergin C, Mulcahy F, Assessing limiting factors to the acceptance of antiretroviral therapy in a large cohort of injecting drug users, HIV Med, 4, (1), 2003, p33 - 37Journal Article, 2003, DOI
  • Clarke S., Mulcahy F., Whats new for IDUs with HIV infection?, Sex Trans Infect, 79, (2), 2003, p80 - 83Journal Article, 2003
  • Hennessy M., Clarke S., Spiers J.P., Kelleher D., Mulcahy F., Hoggard P., Back D., Barry M., Intracellular accumulation of Nelfinavir and its relationship to P-glycoprotein Expression and function in HIV infected patients, Antivir Ther., 8, (3), 2003, p191 - 198Journal Article, 2003
  • M Law, N Friis-Moller, R Weber, ( includes Mulcahy F), Modelling the 3-year risk of myocardial infarction among participants in the Data Collection on Adverse Events of Anti-HIV Drugs (DAD) Study, HIV Medicine, 4, 2003, p1 - 10Journal Article, 2003
  • Alessandro Cozzi-Lepri, Andrew N Phillips, Veronica Miller and EuroSida Study Group ( includes Mulcahy F), Changes in viral load in people with virological failure who remain on the same HAART regimen, Antiviral Therapy, 8, 2003, p127 - 136Journal Article, 2003
  • The Data Collection on adverse events of anti HIV drugs (DAD Study Group. , Combination Antiretroviral therapy and the risk of myocardial infarction, N Engl J Med, 349, 2003, p1993 - 2003Journal Article, 2003
  • DAD Study Group includes Dr Fiona Mulcahy, Lipid Profiles in HIV infected patients receiving combination antiretroviral therapy: Are different antiretroviral drugs associated with different lipid profiles ?, The Journal of Infectious Diseases, 189, (6), 2004Journal Article, 2004
  • A. Mocroft, A. Horban, N. Clumeck, H.J. Stellbrink, d'Arminio A. Monforte, K. Zilmer, O. Kirk, J. Gatell, A.N. Phillips, J.D. Lundgren, Comparison of Single and Boosted Protease Inhibitor Versus Nonnucleoside Reverse Transcriptase Inhibitor-Containing cART Regimens in Antiretroviral-Naïve Patients Starting cART After January 1, 2000 , HIV Clinical Trials, 7, (6), 2007, p271-284Journal Article, 2007, DOI , URL
  • S.L. Pett, H. Wand, M.G. Law, R. Arduino, J.C. Lopez, B. Knysz, L.C. Pereira, S. Pollack, P. Reiss, G. Tambussi, Evaluation of Subcutaneous Proleukin (Interleukin-2) in a Randomized International Trial (ESPRIT): Geographical and Gender Differences in the Baseline Characteristics of Participants, HIV Clinical Trials, 7, (2), 2006, p70-85Journal Article, 2006, DOI , URL
  • A Cozzi-Lepri, L Ruiz, F Ceccherini-Silberstein, A Mocroft, A Phillips, J Gatell, B Ledergerber, P Reiss, B Clotet, JD Lundgren and the EuroSIDA Study group., Mutation at reverse transcriptase codon 214 is antagonist to thymidine analogue mutations type 2 profiles and predicts virological response to thymidine analogue-containing cART regimens only if TAM type 1 profiles concomitantly detected., 13th Conference o­n Retroviruses and Opportunistic Infections, , Denver, February 2006, 2006Poster, 2006
  • Podlekareva D, Mocroft A, Dragsted UB, Ledergerber B, Beniowski M, Lazzarin A, Weber J, Clumeck N, Vetter N, Phillips A, Lundgren JD; EuroSIDA study group., Factors associated with the development of opportunistic infections in HIV-1-infected adults with high CD4 cell counts in the EuroSIDA study., J Infect Dis, 13th Conference o­n Retroviruses and Opportunistic Infections, Denver, February 2006, 194, (5), 2006, pp633-641Poster, 2006, DOI , URL
  • A Mocroft, J Rockstroh, J Gasiorowski, F Antunes, G Panos, A d"Arminio Monforte, A Rakhmanova,, AN Phillips, JD Lundgren, Risk of discontinuation of nevirapine due to toxicitites in antiretroviral naive and experienced patients with high and low CD4 counts. For the EuroSIDA study group. , The XVI International AIDS Conference , Toronto, August 2006, 2006Invited Talk, 2006
  • Z Fox, M Gisslen, B Gazzard, J Kjær, H Nielsen, M Youle, I Cassetti, AN Phillips, UB Dragsted, and JD Lundgren , The ability of four genotypic resistance algorithmis for predicting HIV-RNA responses 4-24 weeks after initiating a boosted PI-containing regimen., 4th European Drug Resistance Workshop, Monte Carlo, March 2006, 2006Poster, 2006, URL
  • WP Bannister, AN Phillips, B Clotet, P Reiss, B Ledergerber, A Lazzarin, C Katlama, A Cozzi-Lepri, L Ruiz, JD Lundgren, Genotypic resistance profile before initiation of cART and association with virological and clinical outcome in EuroSIDA., Eurosida Newsletter, The XVI International AIDS Conference, Toronto, August 2006, 2006Poster, 2006, URL
  • A Mocroft, B Ledergerber, K Zilmer, O Kirk, B Hirschel, JP Viard, P Reiss, P Francioli, A Lazzarin, L Machala, AN Phillips, JD, Short term clinical disease progression in HIV-1 positive patients taking combination antiretroviral therapy: The EuroSIDA risk-score., EuroSIDA Newsletter, The XVI International AIDS Conference, Toronto, August 2006, 2006Conference Paper, 2006, URL
  • ZV Fox, AM Geretti, B Clotet, A Cozzi-Lepri, T Hill, H Green, CA Sabin, B Ledergerber, JD Lundgren and AN Phillips, Association between Resistance and CD4 Count Change in Patients on ART with Ongoing Viraemia., EuroSIDA Fall 2007, XVI International HIV Drug Resistance Workshop, Barbados, June 2007, 2007Poster, 2007, URL
  • A Cozzi-Lepri, AN Phillips, J Martinez-Picado, A d'Arminio Monforte, C Katlama, A-B Eg Hansen, A Horban, J Bruun, B Clotet and J Lundgren, Rate of accumulation of thymidine analogue mutations in patients left on virologically failing regimens containing zidovudine or stavudine. , XVI International HIV Drug Resistance Workshop, Barbados, June 2007, 2007Poster, 2007, URL
  • K Deforche, A Cozzi-Lepri, K Theys, B Clotet, R Camacho, J Kjaer, K Van Laethem, AN Phillips, Y Moreau, JD Lundgren and A-M Vandamme , Proof-of-Principle Evaluation of Predictive Performance for Therapy Outcome of Baseline Estimated Fitness and Genetic Barrier towards Resistance in a Clinical Cohort of HIV-1 Treated Patients., XVI International HIV Drug Resistance Workshop, Barbados, June 2007, 2007Poster, 2007, URL
  • A Mocroft, O Kirk, J Gatell, P Reiss, P Gargalianos, K Zilmer, M Beniowski, JP Viard, S Staszewski, JD Lundgren , Detection of chronic renal failure (CRF) amon HIV-patients within the EuroSIDA Study. , 14th Conference o­n Retroviruses and Opportunistic Infections, Los Angeles, February 2007, 2007Poster, 2007, URL
  • A Mocroft, AN Phillips, J Gatell, B Ledergerber, M Fisher, N Clumeck, M Losso, A Lazzarin, G Fätkenheuer, JD Lundgren, Normalisation of CD4 count in HIV-infected patients with maximal virological suppression (<50 copies/ml) taking combination antiretroviral therapy., 14th Conference o­n Retroviruses and Opportunistic Infections, Los Angeles, February 2007, 2007Poster, 2007, URL
  • Shea DO, Tuite H, Farrell G, Codd M, Mulcahy F, Norris S, Bergin C, Role of rapid virological response in prediction of sustained virological response to Peg-IFN plus ribavirin in HCV / HIV co-infected individuals., Journal of Viral Hepatitis, 15, (7), 2008, p482-489Journal Article, 2008, DOI , URL
  • O'Connor GM, Holmes A, Mulcahy F, Gardiner CM., Natural Killer cells from long-term non-progressor HIV patients are characterized by altered phenotype and function, Clin Immunol. , 124, (3), 2007, p277-83Journal Article, 2007, DOI , URL
  • Holmes A, McMenamin M, Mulcahy F, Bergin C., Thalidomide therapy for the treatment of hypertrophic herpes simplex virus-related genitalis in HIV-infected individuals., Clin Infect Dis., 44, (11), 2007, pe96-9Journal Article, 2007, DOI , URL
  • Kaul P, Walmsley S, Mulcahy F., Antiretroviral rounds. A patient with multiple resistance mutations and a history of nonadherence., AIDS Clin Care. , 18, (12), 2006, p110-1Journal Article, 2006
  • Treacy A, Lyons F, Mulcahy F., Opportunistic cervical screening at a sexual health clinic., Ir Med J. , 99, (7), 2006, p198-9.Journal Article, 2006
  • Lyons F, Butler K, Coulter Smith S, Mulcahy F., National guidelines for the management of HIV-1 in pregnancy., Ir Med J. , 99, (5), 2006, p152-4Journal Article, 2006
  • Lyons F, Hopkins S, Kelleher B, McGeary A, Sheehan G, Geoghegan J, Bergin C, Mulcahy FM, McCormick PA., Maternal hepatotoxicity with nevirapine as part of combination antiretroviral therapy in pregnancy., HIV Med. , 7, (4), 2006, p255-60.Journal Article, 2006, DOI , URL
  • Hopkins S, Lambourne J, Farrell G, McCullagh L, Hennessy M, Clarke S, Mulcahy F, Bergin C., Role of individualization of hepatitis C virus (HCV) therapy duration in HIV/HCV-coinfected individuals., HIV Med. , 7, (4), 2006, p248-54.Journal Article, 2006, DOI , URL
  • Bannister, W.P., Ruiz, L., Cozzi-Lepri, A., Mocroft, A., Kirk, O., Staszewski, S., Loveday, C., Mulcahy, F. (...), Reekie, J., Comparison of genotypic resistance profiles and virological response between patients starting nevirapine and efavirenz in EuroSIDA , AIDS, 22, (3), 2008, p367-376Journal Article, 2008, DOI
  • Fiona Mulcahy and the EuroSIDA Study Group, Hepatitis C Virus (HCV) Coinfection Does Not Influence the CD4 Cell Recovery in HIV-1 Infected Patients with Maximum Virologic Suppression., Journal of Acquired Immune Deficiency Syndromes, 50, (5), 2009, p457-463Journal Article, 2009, DOI
  • M van Luin, WP Bannister, A Mocroft, P Reiss, G Di Perri, G Peytavin, J Molto, A Karlson, A Castagna, M Beniowski, JD Lundgren, DM Burger; the EuroSIDA study group (Includes Mulcahy, F.) , Absence of a relation between efavirenz plasma concentrations and toxicity-driven efavirenz discontinuations in EuroSIDA., Antiviral Therapy, 14, (1), 2009, p75-83Journal Article, 2009
  • J Reekie, A Mocroft, H Sambatakou, L Machala, A Chiesi, J van Lunzen, N Clumeck, O Kirk, B Gazzard, JD Lundgren for the EuroSIDA study group. (Includes Mulcahy, F.), Does less frequent routine monitoring of patients on a stable, fully suppressed cART regimen lead to an increased risk of treatment failure?, aids, 226, (17), 2008, p2381-2390Journal Article, 2008, DOI
  • V Soriano, A Mocroft, J Rockstroh, B Ledergerber, B Knysz, S Chaplinskas, L Peters, A Karlsson, C Katlama, C Toro, B Kupfer, M Vogel and J Lundgren, for the EuroSIDA Study Group. (Includes Mulcahy, F.) , Spontaneous viral clearance, viral load and genotype distribution of hepatitis C virus (HCV) in HIV-infected patients with anti-HCV antibodies in Europe., Journal of Infectious Diseases, 198, (9), 2008, p1337-1344Journal Article, 2008, DOI
  • A Cozzi-Lepri, AN Phillips, B Clotet, A Mocroft, L Ruiz, O Kirk, A Lazzarin, A Wiercinska-Drapalo, A Karlsson, JD Lundgren for the EuroSIDA Study Group. (Includes Mulcahy, F.), Detection of HIV drug resistance during antiretrovrial treatment and clinical progression in a large European cohort study., AIDS, 22, (16), 2008, p2187-2198Journal Article, 2008, DOI
  • D Podlekareva, W Bannister, A Mocroft, L Abrosimova, I Karpov, JD Lundgren, O Kirk for the EuroSIDA study group. (Includes Mulcahy, F.), The EuroSIDA study: regional differences in HIV-1 epidemic and treatment response to antiretroviral therapy among HIV-infected patients across Europe - a review of published results. , Cent Eur J Public Health. , 16, (3), 2008, p99-105Journal Article, 2008
  • WP Bannister, N Friis-Møller, A Mocroft, J-P Viard, J van Lunzen, O Kirk, P Gargalianos, D Bánhegyi, A Chiesi, JD Lundgren, and the EuroSIDA study group. (Includes Mulcahy, F.) , Incidence of abacavir hypersensitivity reactions in EuroSIDA. , Antiviral Therapy, 13, (5-6), 2008, p687-696Journal Article, 2008
  • K Deforche, A Cozzi-Lepri, K Theys, B Clotet, RJ Camacho, J Kjær, K Van Laethem, AN Phillips, Y Moreau, JD Lundgren, and A-M Vandamme on behalf of the EuroSID Study Group. (Includes Mulcahy, F.) , Modelled in vivo HIV fitness under drug selective pressure and estimated genetic barrier towards resistance are predictive for virological response. , Antiviral Therapy, 13, (3), 2008, p399-407Journal Article, 2008
  • CJ Smith, A Mocroft, JD Lundgren; EuroSIDA Study Group. (Includes Mulcahy, F.), Incidence of pancreatitis in HIV-infected patients, and the association with antiretroviral therapy., AIDS, 22, (8), 2008, p997-998Journal Article, 2008, DOI
  • WP Bannister, A Cozzi-Lepri, B Clotet, A Mocroft, J Kjær, P Reiss, V von Wyl, A Lazzarin, C Katlama, AN Phillips, L Ruiz, JD Lundgren and the EuroSIDA study group. (Includes Mulcahy, F.) , Transmitted drug resistance and association with virological and CD4 cell count response to combination antiretroviral therapy in EuroSIDA., J Acquir Immune Defic Syndr., 48, (3), 2008, p324-333Journal Article, 2008, URL
  • A Mocroft, O Kirk, P Aldins, A Chies, A Blaxhult, N Chentsova, N Vetter, F Dabis, J Gatell and JD Lundgren, for the EuroSIDA study group. (Includes Mulcahy, F.) , Loss to follow-up in an international, multicentre observational study. , HIV Medicine, 9, (1), 2009, p261-269Journal Article, 2009, DOI
  • A Mocroft, A Horban, B Clotet, A d'Arminio Monforte, JR Bogner, P Aldins, T Staub, F Antunes, C Katlama, JD Lundgren for the EuroSIDA study group. (Includes Mulcahy, F.) , Regional differences in the risk of triple class failure in European patients starting combination antiretroviral therapy after 1 January 1999, HIV Medicine, 9, (1), 2008, p41-46Journal Article, 2008, DOI
  • Smith CJ, Olsen CH, Mocroft A, Viard JP, Staszewski S, Panos G, Staub T, Blaxhult A, Vetter N, Lundgren JD..Results from the EuroSida Study Group (includes Mulcahy F), The role of antiretroviral therapy on the incidence of pancreatitis in HIV-positive individuals in the EuroSIDA study. , AIDS, 22, (1), 2008, p47-56Journal Article, 2008, DOI
  • Wand H, Calmy A, Carey DL, Samaras K, Carr A, Law MG, Cooper DA, Emery S; INITIO Trial International Coordinating Committee. (includes Mulcahy F) , Metabolic syndrome, cardiovascular disease and type 2 diabetes mellitus after initiation of antiretroviral therapy in HIV infection, AIDS, 21, (18), 2007, p2445-2453Journal Article, 2007, DOI
  • Ceccherini-Silberstein F, Cozzi-Lepri A, Ruiz L, Mocroft A, Phillips AN, Olsen CH, Gatell JM, Gunthard HF, Reiss P, Perno CF, Clotet B, Lundgren JD; EuroSIDA Study Group. (includes Mulcahy F), Impact of HIV-1 reverse transcriptase polymorphism F214L on virological response to thymidine analogue based regimens in ART-naïve and experienced patients., Journal of Infectious Diseases, 196, (8), 2007, p1180-1190Journal Article, 2007, DOI
  • Kowalska JD, Mocroft A, Blaxhult A, Colebunders R, van Lunzen J, Podlekareva D, Hansen AB, Machala L, Yust I, Benfield T; for the EuroSIDA Study Group. (includes Mulcahy F), Current haemoglobin levels are more predictive of disease progression than haemoglobin measured at baseline in patients receiving antiretroviral treatment for HIV-1 infection. , AIDS Research and Human Retroviruses. , 23, (10), 2008, p1183-1188Journal Article, 2008, DOI
  • Mocroft A, Ledergerber B, Zilmer K, Kirk O, Hirschel B, Viard JP, Reiss P, Francioli P, Lazzarin A, Machala L, Phillips AN, Lundgren JD; EuroSIDA study group and the Swiss HIV Cohort Study. (includes Mulcahy F), Short term clinical disease progression in HIV-1 positive patients taking combination antiretroviral therapy: The EuroSIDA risk-score., AIDS, 21, (14), 2007, p1867-1875Journal Article, 2007, DOI
  • Mocroft A, Phillips AN, Gatell J, Ledergerber B, Fisher M, Clumeck N, Losso M, Lazzarin A, Fatkenheuer G, Lundgren JD; EuroSIDA study group. (includes Mulcahy F), Normalisation of CD4 counts in patients with HIV-1 infection and maximum virological suppression who are taking combination antiretroviral therapy: an observational cohort study. , Lancet Oncology, 370, (9585), 2007, p407-413Journal Article, 2007, DOI
  • Mocroft A, Kirk O, Gatell J, Reiss P, Gargalianos P, Zilmer K, Beniowski M, Viard JP, Staszewski S, Lundgren JD. EuroSida Study Group (includes Mulcahy F), Chronic renal failure among HIV-1-infected patients. , AIDS, 21, (9), 2007, p1119-1127Journal Article, 2007, DOI
  • Holkmann Olsen C, Mocroft A, Kirk O, Vella S, Blaxhult A, Clumeck N, Fisher M, Katlama C, Phillips AN, Lundgren JD; EuroSIDA study group. (includes Mulcahy F), Interruption of combination antiretroviral therapy and risk of clinical disease progression to AIDS or death. , HIV Medicine, 8, (2), 2007, p96-104Journal Article, 2007, DOI
  • Mocroft Amanda; Rockstroh Jurgen; Soriano Vincent; Kirk Ole; Viard Jean-Paul; Caplinskas Saulius; Gasiorowski Jacek; Chiesi Antonio; Phillips Andrew N; Lundgren Jens D; EuroSIDA Study Group (includes Mulcahy F), Limited but increasing use of treatment for hepatitis C across Europe in patients coinfected with HIV and hepatitis C., Scandinavian Journal of infectious diseases, 38, (11-12), 2006, p1092-1097Journal Article, 2006
  • Bannister Wendy P; Ruiz Lidia; Loveday Clive; Vella Stefano; Zilmer Kai; Kjaer Jesper; Knysz Brygida; Phillips Andrew N; Mocroft Amanda; EuroSida Study Group (includes Mulcahy F), HIV-1 subtypes and response to combination antiretroviral therapy in Europe., Antiviral therapy , 11, (6), 2006, p707-715Journal Article, 2006
  • May MT, Sterne JA, Costagliola D, Sabin CA, Phillips AN, Justice AC, Dabis F, Gill J, Lundgren J, Hogg RS, de Wolf F, Fätkenheuer G, Staszewski S, d'Arminio Monforte A, Egger M; Antiretroviral Therapy (ART) Cohort Collaboration (includes Mulcahy F), HIV treatment response and prognosis in Europe and north America in the first decade of highly active antiretroviral therapy: a collaboration analysis., Lancet., 368, (9534), 2006, p451-458Journal Article, 2006, DOI
  • Puoti M, Cozzi-Lepri A, Paraninfo G, Arici C, Moller NF, Lundgren JD, Ledergerber B, Rickenbach M, Suarez-Lozano I, Garrido M, Dabis F, Winnock M, Milazzo L, Gervais A, Raffi F, Gill J, Rockstroh J, Ourishi N, Mussini C, Castagna A, De Luca A, Monforte A; HBV-HIV International Intercohort Study Group. EuroSida Study Group (includes Mulcahy F), Impact of lamivudine on the risk of liver related death in 2,041 HbsAg - and HIV positive individuals: result from an inter-cohort analysis., Antiviral Therapy , 11, (5), 2006, p567-574Journal Article, 2006, URL
  • Weber R, Sabin CA, Friis-Møller N, Reiss P, El-Sadr WM, Kirk O, Dabis F, Law MG, Pradier C, De Wit S, Akerlund B, Calvo G, Monforte A, Rickenbach M, Ledergerber B, Phillips AN, Lundgren JD., Liver related deaths among persons infected with the human immunodeficiency virus: the D:A:D Study, Archives of Internal Medicine, 166, (15), 2006, p1632-1641Journal Article, 2006, URL
  • Bannister WP, Kirk O, Gatell JM, Knysz B, Viard JP, Mens H, Monforte AD, Phillips AN, Mocroft A, Lundgren JD; EuroSIDA Study Group.(includes Mulcahy F), Regional changes over time in initial virological response rates to combination antiretroviral therapy across Europe. , Journal of Acquired Immune Deficiency Syndromes, 42, (2), 2006, p229-237Journal Article, 2006, URL
  • Mocroft A, Neaton J, Bebchuk J, Staszewski S, Antunes F, Knysz B, Law M, Phillips AN, Lundgren JD; EuroSIDA Study Group (includes Mulcahy F) ESPRIT Study Group, The feasibility of clinical endpoint trials in HIV infection in the highly active antiretroviral treatment (HAART) era. , Clinical Trials, 3, (2), 2006, p119-132Journal Article, 2006, URL
  • Mocroft A, Phillips AN, Ledergerber B, Katlama C, Chiesi A, Goebel FD, Knysz B, Antunes F, Reiss P, Lundgren JD. EuroSida Study Group (includes Mulcahy F), Relationship between antiretrovirals used as part of a cART regimen and CD4 count increases in patients with suppressed viremia. , AIDS, 20, (8), 2006, p1141-1150Journal Article, 2006, DOI
  • Podlekareva D, Mocroft A, Dragsted UB, Ledergerber B, Beniowski M, Lazzarin A, Weber J, Clumeck N, Vetter N, Phillips A, Lundgren JD; EuroSIDA study group.(includes Mulcahy F), Factors associated with development of opportunistic infections in HIV-1 infected adults with high CD4 cell counts, Journal of Infectious Diseases, 194, (1), 2006, p663-641Journal Article, 2006
  • Phillips AN, Ledergerber B, Horban A, Reiss P, Chiesi A, Kirk O, Mulchany F, Fisher M, Machala L, Lundgren JD; EuroSIDA Study Group. (includes Mulcahy F), Rate of viral rebound according to specific drugs in the regimen in 2120 patients with HIV suppression. , AIDS, 18, (3), 2004, p1795-1804Journal Article, 2004
  • Lactic Acidosis International Study Group, Risk factors for lactic acidosis and severe hyperlactataemia in HIV-1-infected adults exposed to antiretroviral therapy, AIDS , 21, (18), 2007, p2455-2464Journal Article, 2007, DOI
  • INITIO Trial International Co-ordinating Committee, Yeni P, Cooper DA, Aboulker JP, Babiker AG, Carey D, Darbyshire JH, Floridia M, Girard PM, Goodall RL, Hooker MH, Mijch A, Meiffredy V, Salzberger B., Virological and immunological outcomes at 3 years after starting antiretroviral therapy with regimens containing non-nucleoside reverse transcriptase inhibitor, protease inhibitor, or both in INITIO: open-label randomised trial., Lancet, 368, (9532), 2006, p287-98Journal Article, 2006, DOI
  • Fiona Mulcahy, The Collaboration of Observational HIV Epidemiological Research Europe (COHERE) study group, Prognosis of HIV-associated non-Hodgkin lymphoma in patients starting combination antiretroviral therapy, AIDS, 23, (15), 2009, p2029-2037Journal Article, 2009, DOI , URL
  • Fiona Mulcahy, The When To Start Consortium, Timing of initiation of antiretroviral therapy in AIDS-free HIV-1-infected patients: a collaborative analysis of 18 HIV cohort studies, Lancet, 373, (9672), 2009, p1352-1363Journal Article, 2009, DOI
  • Fiona Mulcahy, The Data Collection on Adverse events of Anti-HIV Drugs (D:A:D) study, Presence of the metabolic syndrome is not a better predictor of cardiovascular disease than the sum of its components in HIV-infected individuals: data collection on adverse events of anti-HIV drugs (D:A:D) study, Diabetes Care, 32, (3), 2009, p474-480Journal Article, 2009, DOI
  • Fiona Mulcahy, The Data Collection on Adverse events of Anti-HIV Drugs (D:A:D) study, Diabetes mellitus, preexisting coronary heart disease, and the risk of subsequent coronary heart disease events in patients infected with human immunodeficiency virus: the Data Collection on Adverse Events of Anti-HIV Drugs (D:A:D Study). , Circulation, 119, (6), 2009, p805 - 811Journal Article, 2009, DOI
  • Fiona Mulcahy, The Nevirapine Toxicity Multicohort Collaboration., Risk factors for treatment-limiting toxicities in patients starting nevirapine-containing antiretroviral therapy, AIDS, 23, (13), 2009, p1689-1699Journal Article, 2009, DOI
  • Fiona Mulcahy, The EuroSIDA Study Group, Rate of Accumulation of Thymidine Analogue Mutations in Patients Continuing to Receive Virologically Failing Regimens Containing Zidovudine or Stavudine: Implications for Antiretroviral Therapy Programs in Resource-Limited Settings, The Journal of Infectious Diseases, 200, (5), 2009, p687-697Journal Article, 2009, DOI
  • Fiona Mulcahy, The SWEET (Simplification With Easier Emtricitabine Tenofovir) group UK, A randomized comparative trial of continued Zidovudine/Lamivudine or replacement with Tenofovir Disoproxil Fumarate/Emtricitabine in Efavirenz treated HIV-1 infected individuals, Journal of Acquired Immune Deficiency Syndromes, 51, (5), 2009, p562-568Journal Article, 2009, DOI
  • Fiona Mulcahy, The INSIGHT-ESPRIT Study Group, Interleukin - 2 therapy in patients with HIV infection, The New England Journal of Medicine, 361, (16), 2009, p1548-1559Journal Article, 2009, URL
  • A. Loy, Mulcahy, F, Review of Overview of Genital Warts , Modern Medicine, 2, (29), 2009, p36-40Review, 2009
  • Fiona Mulcahy, The EuroSIDA Study Group, History of viral suppression on combination antiretroviral therapy as a predictor of virological failure after a treatment change, HIV Medicine, 2010Journal Article, 2010, DOI
  • Fiona Mulcahy, The EuroSIDA Study Group, Estimated average annual rate of change of CD4 counts in patients on combination antiretroviral therapy, Antiviral Therapy, 2010Journal Article, 2010
  • Fiona Mulcahy, The EuroSIDA Study Group, Predictors of hepatitis B virus (HBV) genotype and viremia in HIV-infected patients with chronic hepatitis B in Europe, Journal of Antimicrobial Chemotherapy, 2010Journal Article, 2010
  • Kennedy A, Hennessy M, Bergin C, Mulcahy F, Hopkins S, Spiers JP, Ribavirin and interferon alter MMP-9 abundance in vitro and in HIV-HCV-coinfected patients., Antiviral therapy, 16, (8), 2011, p1237-47Journal Article, 2011
  • Esser S, Haberl A, Mulcahy F, Gölz J, Lazzarin A, Teofilo E, Vera J, Körber A, Staszewski S, Efficacy, adherence and tolerability of once daily tenofovir DF-containing antiretroviral therapy in former injecting drug users with HIV-1 receiving opiate treatment: results of a 48-week open-label study., European Journal of Medical Research, 16, (10), 2011, p427-36Journal Article, 2011
  • Kieran J, Dillon A, Farrell G, Jackson A, Norris S, Mulcahy F, Bergin C, High uptake of hepatitis C virus treatment in HIV/hepatitis C virus co-infected patients attending an integrated HIV/hepatitis C virus clinic., International journal of STD & AIDS, 22, (10), 2011, p571-6Journal Article, 2011, DOI , URL
  • Pett SL, Carey C, Lin E, Wentworth D, Lazovski J, Miró JM, Gordin F, Angus B, Rodriguez-Barradas M, Rubio R, Tambussi G, Cooper DA, Emery S, Predictors of bacterial pneumonia in Evaluation of Subcutaneous Interleukin-2 in a Randomized International Trial (ESPRIT)., HIV medicine, 12, (4), 2011, p219-27Journal Article, 2011, DOI , URL
  • Bannister WP, Cozzi-Lepri A, Kjær J, Clotet B, Lazzarin A, Viard JP, Kronborg G, Duiculescu D, Beniowski M, Machala L, Phillips A, Estimating prevalence of accumulated HIV-1 drug resistance in a cohort of patients on antiretroviral therapy., The Journal of antimicrobial chemotherapy, 66, (4), 2011, p901-11Journal Article, 2011, DOI , URL
  • Petoumenos K, Worm S, Reiss P, de Wit S, d'Arminio Monforte A, Sabin C, Friis-Møller N, Weber R, Mercie P, Pradier C, El-Sadr W, Kirk O, Lundgren J, Law M, Rates of cardiovascular disease following smoking cessation in patients with HIV infection: results from the D:A:D study(*)., HIV medicine, 12, (7), 2011, p412-21Journal Article, 2011, DOI , URL
  • Kowalska JD, Mocroft A, Ledergerber B, Florence E, Ristola M, Begovac J, Sambatakou H, Pedersen C, Lundgren JD, Kirk O, A standardized algorithm for determining the underlying cause of death in HIV infection as AIDS or non-AIDS related: results from the EuroSIDA study., HIV clinical trials, 12, (2), 2011, p109-17Journal Article, 2011, DOI , URL
  • Kruk A, Bannister W, Podlekareva DN, Chentsova NP, Rakhmanova AG, Horban A, Domingo P, Mocroft A, Lundgren JD, Kirk O, Tuberculosis among HIV-positive patients across Europe: changes over time and risk factors., AIDS (London, England), 25, (12), 2011, p1505-13Journal Article, 2011
  • Viard JP, Souberbielle JC, Kirk O, Reekie J, Knysz B, Losso M, Gatell J, Pedersen C, Bogner JR, Lundgren JD, Mocroft A, Vitamin D and clinical disease progression in HIV infection: results from the EuroSIDA study., AIDS (London, England), 25, (10), 2011, p1305-15Journal Article, 2011
  • Bohlius J, Schmidlin K, Boué F, Fätkenheuer G, May M, Caro-Murillo AM, Mocroft A, Bonnet F, Clifford G, Paparizos V, Miro JM, Obel N, Prins M, Chêne G, Egger M, HIV-1-related Hodgkin lymphoma in the era of combination antiretroviral therapy: incidence and evolution of CD4+ T-cell lymphocytes., Blood, 117, (23), 2011, p6100-8Journal Article, 2011, DOI , URL
  • Kowalska JD, Friis-Møller N, Kirk O, Bannister W, Mocroft A, Sabin C, Reiss P, Gill J, Lewden C, Phillips A, D'Arminio Monforte A, Law M, Sterne J, De Wit S, Lundgren JD, The Coding Causes of Death in HIV (CoDe) Project: initial results and evaluation of methodology., Epidemiology (Cambridge, Mass.), 22, (4), 2011, p516-23Journal Article, 2011, DOI , URL
  • Fox ZV, Cozzi-Lepri A, D'Arminio Monforte A, Karlsson A, Phillips AN, Kronborg G, Kjaer J, Clotet B, Lundgren JD, Predictors of having a resistance test following confirmed virological failure of combination antiretroviral therapy: data from EuroSIDA., Antiviral therapy, 16, (5), 2011, p781-5Journal Article, 2011
  • Soriano V, Grint D, d'Arminio Monforte A, Horban A, Leen C, Poveda E, Antunes F, de Wit S, Lundgren J, Rockstroh J, Peters L, Hepatitis delta in HIV-infected individuals in Europe., AIDS (London, England), 25, (16), 2011, p1987-92Journal Article, 2011
  • Reekie J, Gatell JM, Yust I, Bakowska E, Rakhmanova A, Losso M, Krasnov M, Francioli P, Kowalska JD, Mocroft A, Fatal and nonfatal AIDS and non-AIDS events in HIV-1-positive individuals with high CD4 cell counts according to viral load strata., AIDS (London, England), 25, (18), 2011, p2259-68Journal Article, 2011
  • Reekie, J, Reiss, P, Ledergerber, B, Sedlacek, D, Parczewski, M, Gatell, J, Katlama, C, Fatkenheuer, G, Lundgren, JD, Mocroft, A, A comparison of the long-term durability of nevirapine, efavirenz and lopinavir in routine clinical practice in Europe: a EuroSIDA study, HIV MEDICINE, 12, (5), 2011, p259-68Journal Article, 2011, DOI , URL
  • Paredes R, Puertas MC, Bannister W, Kisic M, Cozzi-Lepri A, Pou C, Bellido R, Betancor G, Bogner J, Gargalianos P, Bánhegyi D, Clotet B, Lundgren J, Menéndez-Arias L, Martinez-Picado J, A376S in the connection subdomain of HIV-1 reverse transcriptase confers increased risk of virological failure to nevirapine therapy., The Journal of infectious diseases, 204, (5), 2011, p741-52Journal Article, 2011, DOI , URL
  • Cozzi-Lepri A, Prosperi MC, Kjær J, Dunn D, Paredes R, Sabin CA, Lundgren JD, Phillips AN, Pillay D, Can linear regression modeling help clinicians in the interpretation of genotypic resistance data? An application to derive a lopinavir-score., PloS one, 6, (11), 2011, pe25665Journal Article, 2011, DOI , URL
  • Cozzi-Lepri A, Paredes Phillips AN, Clotet B, Kjaer J, Von Wyl V, Kronborg G, Castagna A, Bogner JR, Lundgren JD, The rate of accumulation of nonnucleoside reverse transcriptase inhibitor (NNRTI) resistance in patients kept on a virologically failing regimen containing an NNRTI*., HIV medicine, 13, (1), 2012, p62-72Journal Article, 2012, DOI , URL
  • Worm SW, Kamara DA, Reiss P, Kirk O, El-Sadr W, Fux C, Fontas E, Phillips A, D'Arminio Monforte A, De Wit S, Petoumenos K, Friis-Møller N, Mercie P, Lundgren JD, Sabin C, Elevated triglycerides and risk of myocardial infarction in HIV-positive persons., AIDS (London, England), 25, (12), 2011, p1497-504Journal Article, 2011
  • DA Kamara, SW Worm, P Reiss, M Rickenbach, A Phillips, O Kirk, AD Monforte, M Bruyand, M Law, S De Wit, C Smith, C Pradier, JD Lundgren, C Sabin, The impact of fasting on the interpretation of triglyceride levels for predicting myocardial infarction risk in HIV-positive individuals: the D:A:D study., The Journal of infectious diseases, 204, (4), 2011, p521-5Journal Article, 2011, DOI , URL
  • Muldoon EG, Mooka B, Reidy D, O'Dea S, Clarke S, Courtney G, Lyons F, Bergin C, Mulcahy F, Long-term neurological follow-up of HIV-positive patients diagnosed with syphilis., International journal of STD & AIDS, 23, (9), 2012, p676-8Journal Article, 2012
  • Muldoon EG, Walsh A, Crowley B, Mulcahy F, Treponema pallidum azithromycin resistance in Dublin, Ireland., Sexually transmitted diseases, 39, (10), 2012, p784-6Journal Article, 2012
  • Worm SW, Kamara DA, Reiss P, Fontas E, De Wit S, El-Sadr W, D'Arminio Monforte A, Law M, Phillips A, Ryom L, Dabis F, Weber R, Sabin C, Lundgren JD, Evaluation of HIV protease inhibitor use and the risk of sudden death or nonhemorrhagic stroke., The Journal of infectious diseases, 205, (4), 2012, p535-9Journal Article, 2012
  • Nakagawa F, Lodwick RK, Smith CJ, Smith R, Cambiano V, Lundgren JD, Delpech V, Phillips AN, Projected life expectancy of people with HIV according to timing of diagnosis., AIDS (London, England), 26, (3), 2012, p335-43Journal Article, 2012
  • Kowalska JD, Reekie J, Mocroft A, Reiss P, Ledergerber B, Gatell J, d'Arminio Monforte A, Phillips A, Lundgren JD, Kirk O, Long-term exposure to combination antiretroviral therapy and risk of death from specific causes: no evidence for any previously unidentified increased risk due to antiretroviral therapy., AIDS (London, England), 26, (3), 2012, p315-23Journal Article, 2012
  • Petoumenos K, Worm SW, Fontas E, Weber R, De Wit S, Bruyand M, Reiss P, El-Sadr W, Monforte AD, Friis-Møller N, Lundgren JD, Law MG, Predicting the short-term risk of diabetes in HIV-positive patients: the Data Collection on Adverse Events of Anti-HIV Drugs (D:A:D) study., Journal of the International AIDS Society, 15, (2), 2012, p17426Journal Article, 2012
  • Duprez DA, Neuhaus J, Kuller LH, Tracy R, Belloso W, De Wit S, Drummond F, Lane HC, Ledergerber B, Lundgren J, Nixon D, Paton NI, Prineas RJ, Neaton JD, Inflammation, coagulation and cardiovascular disease in HIV-infected individuals., PloS one, 7, (9), 2012, pe44454Journal Article, 2012
  • Mocroft A, Bannister WP, Kirk O, Kowalska JD, Reiss P, D'Arminio-Monforte A, Gatell J, Fisher M, Trocha H, Rakhmanova A, Lundgren JD, The clinical benefits of antiretroviral therapy in severely immunocompromised HIV-1-infected patients with and without complete viral suppression., Antiviral therapy, 17, (7), 2012, p1291-300Journal Article, 2012
  • Mocroft A, Neuhaus J, Peters L, Ryom L, Bickel M, Grint D, Koirala J, Szymczak A, Lundgren J, Ross MJ, Wyatt CM, Hepatitis B and C co-infection are independent predictors of progressive kidney disease in HIV-positive, antiretroviral-treated adults., PloS one, 7, (7), 2012, pe40245Journal Article, 2012
  • May MT, Hogg RS, Justice AC, Shepherd BE, Costagliola D, Ledergerber B, Thiébaut R, Gill MJ, Kirk O, van Sighem A, Saag MS, Navarro G, Sobrino-Vegas P, Lampe F, Ingle S, Guest JL, Crane HM, D'Arminio Monforte A, Vehreschild JJ, Sterne JA, Heterogeneity in outcomes of treated HIV-positive patients in Europe and North America: relation with patient and cohort characteristics., International journal of epidemiology, 41, (6), 2012, p1807-20Journal Article, 2012
  • Benchmarking HIV health care: from individual patient care to health care evaluation. An example from the EuroSIDA study., D Podlekareva, J Reekie, A Mocroft, M Losso, A Rakhmanova, E Bakowska, IA Karpov, J Lazarus, J Gatell, JD Lundgren, O Kirk., BMC Infect Dis. , 12, (1), 2012Journal Article, 2012
  • CLARKE, SM, AN OUTBREAK OF SERIOUS UNEXPLAINED ILLNESS IN INJECTING DRUG USERS IN EUROPE - THE EXPERIENCE OF AN IRISH INSTITUTION, 2001, 33, ISI Web of Science, 2001, pp1119 - 1119Meeting Abstract
  • MERRY, C, AN OVERDOSE OF POST EXPOSURE PROPHYLAXIS IN A PREGNANT WOMAN., 1998, 12, ISI Web of Science, 1998, ppS57 - S57Meeting Abstract
  • CLARKE, S, ANALYSING LIMITING FACTORS IN THE ACCEPTANCE OF HAART IN INJECTION DRUG USERS (IDUS), 2000, 14, ISI Web of Science, 2001, ppS45 - S45Meeting Abstract
  • MULCAHY, F, ANTIVIRAL THERAPY AND MANAGEMENT OF HIV IN INTRAVENOUS DRUG USERS, 2000, 14, ISI Web of Science, 2001, ppS2 - S2Meeting Abstract
  • RYAN, M, CHANGING DEMOGRAPHICS OF AN IRISH HIV-INFECTED COHORT FROM 1995 TO 1999, 2000, 14, ISI Web of Science, 2001, ppS137 - S137Meeting Abstract
  • MILLER, V, LOVEDAY, C, STASZEWSKI, S, LUNDGREN, J, YOULE, M, AIT-KHALED, M, BOUCHER, C, BRUN-VEZINET, F, DEDES, N, GIAQUINTO, C, HERTOGS, K, HOUYEZ, F, PERRIN, L, PILLAY, D, SCHMIT, JC, SCHUURMAN, R, LANGE, J, BANHEGYI, D, BIONDI, G, BROEKHUIZEN, A, BUSH-DONOVAN, C, CAMACHO, R, CARLIER, H, CLAVEL, F, CLOTET, B, CLUMECK, N, COLEBUNDERS, R, DE CLERQ, K, DE JAEGHER, JJ, DE SCHRIJVER, G, DE SMET, K, HALL, W, HARRIGAN, R, HATZAKIS, A, HELLMANN, N, HOETELMANS, R, HOLTZER, C, KATLAMA, C, LARDER, D, LORIAUX, E, MCCREEDY, B, MULCAHY, F, OPRAVIL, M, PHILLIPS, A, RUIZ, N, SHULSE, E, SONNERBORG, A, SORIANO, V, STEEL, H, VELLA, S, WILLIAMS, A, CLINICAL AND LABORATORY GUIDELINES FOR THE USE OF HIV-1 DRUG RESISTANCE TESTING AS PART OF TREATMENT MANAGEMENT: RECOMMENDATIONS FOR THE EUROPEAN SETTING, by VANDAMME, AM , AIDS, 15, 2001Review
  • COUGHLAN, S, CLINICAL UTILITY OF HIV-1 GENOTYPIC DRUG RESISTANCE TESTING IN A HETEROGENEOUS, NON-TRIAL POPULATION, 2000, 14, ISI Web of Science, 2001, ppS116 - S117Meeting Abstract
  • MCMAHON, C, COCAINE-INDUCED THROMBOCYTOPENIA IN A YOUNG HIV SEROPOSITIVE INJECTING DRUG USER, 2000, 14, ISI Web of Science, 2001, ppS67 - S67Meeting Abstract
  • CONDON, S, COMBINATION ANTIRETROVIRAL THERAPY (ART) IN PREGNANCY: INFANT OUTCOME, 1998, 12, ISI Web of Science, 1998, ppS94 - S94Meeting Abstract
  • RYAN, M, DETERMINING THE COST OF HOSPITALISATION OF HIV-INFECTED PATIENTS IN IRELAND IN ORDER TO ASSESS THE PHARMACOECONOMIC IMPACT OF HAART ON INPATIENT CARE, 2000, 14, ISI Web of Science, 2001, ppS101 - S101Meeting Abstract
  • HARRINGTON, P, EFFICACY AND TOLERABILITY OF HYDROXYUREA CONTAINING SALVAGE ANTIRETROVIRAL REGIMENS IN THE MANAGEMENT OF HIV INFECTION, 2000, 14, ISI Web of Science, 2001, ppS35 - S35Meeting Abstract
  • FAY, L, ERYTHRODYSETHESIA FOLLOWING DOXORUBICIN THERAPY FOR KAPOSI'S SARCOMA, 2000, 14, ISI Web of Science, 2001, ppS67 - S67Meeting Abstract
  • HOPKINS, S, HEPATITIS C: PREVALENCE AND IMPLICATIONS FOR TREATMENT IN THE HIV CO-INFECTED POPULATION, 2000, 14, ISI Web of Science, 2001, ppS125 - S125Meeting Abstract
  • BARRY, M, HYDROXYUREA-INDUCED NEUROTOXICITY IN HIV DISEASE, 1999, -Miscellaneous
  • MURPHY, N, IMMUNOCYTOCHEMICAL ANALYSIS OF P16 PROTEIN EXPRESSION IN CERVICAL CANCER AND CERVICAL INTRAEPITHELIAL NEOPLASIA., 2001, 195, ISI Web of Science, 2001, pp2A - 2AMeeting Abstract
  • BACK, D, INTERACTIONS BETWEEN ANTIRETROVIRALS, 1998, 12, ISI Web of Science, 1998, ppS6 - S6Meeting Abstract
  • HENNESSY, M, INTRACELLULAR INDINAVIR PHARMACOKINETICS IN HIV POSITIVE PATIENTS, 2000, 14, ISI Web of Science, 2001, ppS97 - S97Meeting Abstract
  • MCGRATH, E, LIFE-SAVING CHEMOTHERAPY FOR KAPOSI'S SARCOMA IN A HIV POSITIVE PREGNANT WOMAN, 2000, 14, ISI Web of Science, 2001, ppS131 - S131Meeting Abstract
  • CURRAN, S, MYOCARDIAL INFARCTION AND PROTEASE INHIBITOR THERAPY: TWO CASE REPORTS, 2000, 14, ISI Web of Science, 2001, ppS62 - S62Meeting Abstract
  • MURPHY, N, P16INK4A, CDC6, MCM5 AND HPV STATUS: PREDICTIVE BIOMARKERS OF CERVICAL PRE-NEOPLASIA?, unknown, 2002, 198, ISI Web of Science, 2002, pp16A - 16AMeeting Abstract
  • BARRY, M, PHARMACOKINETICS AND POTENTIAL INTERACTIONS AMONGST ANTIRETROVIRAL AGENTS USED TO TREAT PATIENTS WITH HIV INFECTION, by MULCAHY, F , CLINICAL PHARMACOKINETICS, 36, 1999Review
  • CLARKE, S, MERRY, C, MORAN, AM, MULCAHY, F, PNEUMOCOCCAL PNEUMONIA ASSOCIATED WITH PERIANAL HERPES SIMPLEX VIRUS TYPE 2 IN A HIV SEROPOSITIVE PATIENT, 1999, -Miscellaneous
  • BARRY, M, RITONAVIR INDUCED HYPERLIPIDAEMIA IN PATIENTS WITH HIV DISEASE, 1998, 12, ISI Web of Science, 1998, ppS52 - S52Meeting Abstract
  • HENNESSY, M, ST JOHN'S WORT MODULATES BOTH EXPRESSION AND FUNCTION OF P GLYCOPROTEIN IN PERIPHERAL BLOOD LYMPHOCYTES, 2000, 14, ISI Web of Science, 2001, ppS95 - S95Meeting Abstract
  • MC MAHON, C, SUCCESSFUL USE OF PROTEASE INHIBITORS IN HIV-INFECTED PATIENTS WITH HAEMOPHILIA, 1998, 101, ISI Web of Science, 1998, pp87 - 87Meeting Abstract
  • CLARKE, S, THE ACTIVE MANAGEMENT OF HIV IN PREGNANCY, 2000, 14, ISI Web of Science, 2001, ppS138 - S139Meeting Abstract
  • CLARKE, S, THE PHARMACOKINETIC INTERACTION BETWEEN METHADONE AND NELFINAVIR, 2000, 14, ISI Web of Science, 2001, ppS95 - S95Meeting Abstract
  • The Initio Co-Ordinating Committee, ( includes Mulcahy F), An open-label randomised trial to evaluate different therapeutic strategies of combination therapy in HIV-1 Infection: Design, Rationale and methods of the Initio trial, Controlled Clinical Trials, 22, (2), 2001Journal Article
  • Dr Fiona Mulcahy - Principal Investigator for St James Hospital, Dublin, A randomised, open label. phase III, international study of subcutaneous recombinant IL-2 (Proleukin) in patients with HIV-1 infection and CD4 cell counts > 300/mm3: Evaluation of Subcutaneous Proleukin in a randomised international trial (ESPRIT)Report
  • Dr Fiona Mulcahy - Principal Investigator for St James Hospital, Dublin, An open-label comparative study to evaluate the antiviral efficacy and safety of Nevirapine and Efavirenz or both drugs combined in combination with d4T and 3TC (2NN study)Report
  • Dr Fiona Mulcahy - Principal Investigator for St James Hospital, Dublin, A phase IV randomised open-label trial to evaluate the safety and efficacy of continued 3TC twice-daily therapy versus discontinuation of 3TC, as part of the second-line treatment of HIV-1 infection in patients who have shown virological failure on first-line combination treatments containing 3TC (Colate)Report
  • Dr Fiona Mulcahy - Principal Investigator for St James Hospital, Dublin, An open label pharmacokinetic study to evaluate the interaction between Nevirapine and Methadone in HIV-1 infected, opoid-dependent adults on stable methadone maintenance therapy. (Methadone/Neviripine study)Report
  • Dr Fiona Mulcahy - Principal Investigator for St James Hospital, Dublin, A randomised open-label. comparative safety and efficacy study of tipranavir boosted with low dose ritonavir versus genotypically-defined protease inhibitor/ritonavir in multiple antiretroviral drug-experienced patients (Resist 2 1182.48)Report
  • Dr Fiona Mulcahy - Principal Investigator for St James Hospital, Dublin, A long term open-label rollover trial assessing the safety and tolerability of combination tipranavir and ritonavir use in HIV-1 infected subjects. (Resist 1182.17)Report
  • 2NN Study Group includes Dr Fiona Mulcahy, Comparison of first-line antiretroviral therapy with regimens including Nevirapine, Efavirenz or both drugs, plus stavudine and lamivudine: a randomised open-label trail, the 2NN Study, The Lancet, 363, (9417)Journal Article
  • EuroSIDA study Group includes Dr Fiona Mulcahy, Changing Incidence of central nervous system diseases in EuroSIDA cohort, American Neurological Association, 2004Journal Article
  • Results from the EuroSida Study Group. (includes Mulcahy F), Changes in hospital admission across Europe: 1995 - 2003, HIV Medicine, 5, 2004, p437 - 447Journal Article
  • F. Lyons, S. Hopkins, A. Mc Geary, G. Sheehan, C. Bergin, and F. Mulcahy, Nevirapine tolerability in HIV infected women in pregnancy - A word of caution, Late breaker 27, 2nd IAS conference on HIV pathogenesis and treatment, Paris, France, July, 2003Meeting Abstract
  • S Hopkins, H McDermott, F Lyons, C Bergin and F Mulcahy, Syphilis and the central nervous system (CNS) in HIV infected patients, 2nd IAS Conference on HIV pathogenesis and treatment, Paris, 2003Meeting Abstract
  • F Lyons, S Hopkins, C Bergin and F Mulcahy, Maternal tolerability of antiretroviral therapy (art) in preventing vertical transmission (vt) of HIV-1, 9th European AIDS Conference, Warsaw, Poland, October, 2003Meeting Abstract
  • S. Hopkins, F. Lyons, E. Brannigan, F. Mulcahy, C. Bergin, Pegylated Interferon and Ribavirin in HIV-HCV Coinfected Patients (Oral Presentation), British Infection Society, 6th Annual Scientific Meeting, London, 2003Meeting Abstract
  • S. Hopkins, E. Brannigan, F. Lyons, H. McDermott, F. Mulcahy, C. Bergin, The Impact of treatment with Pegylated Interferon and Ribavirin on ART Prescribing in HIV-HCV Coinfected Patients. (Oral Presentation), Clinical Microbiology & Infection, 13th European Congress of Clinical Microbiology & Infectious Diseases, Glasgow, 9, (Supplement 1), 2003, pp52-O281Meeting Abstract
  • S. Hopkins, L. Thornton, M. Fitzgerald, C. Merry, C. Bergin, F. Mulcahy, Case Finding Strategies in a Syphilis Outbreak, Clinical Microbiology & Infection, 13th European Congress of Clinical Microbiology & Infectious Diseases, Glasgow, 9, (Supplement 1), 2003, pp277 - P1171Meeting Abstract
  • E. Brannigan, S. Hopkins, P. Coakley, F. Mulcahy, C. Bergin, Impact of Migration on the Prevalence of Mycobacterial Infections in HIV-postive Patients in Ireland, 13th European Congress of Clinical Microbiology & Infectious Diseases, Glasgow, 2003Meeting Abstract
  • S. Hopkins, G. Farrell, F. Mulcahy. C. Bergin, HIV-HCV Coinfection : To Treat or Not to Treat, Antiviral Therapy, 2nd International AIDS Society Conference on HIV Pathogenesis and Treatment, Paris, 8, (Supplement 1), 2003, ppS458 - 459Meeting Abstract
  • DAD study (Includes Mulcahy F), Predictors of hypertension and changes in blood pressure in HIV infected patients, 11th Conference on Retroviruses and Opportunistic Infections, February, 2004Meeting Abstract
  • E Devitt, S Hopkins, F Mulcahy, C Bergin, Rising number os HIV infection after a syphilis epidemic, 11th Conference on Retroviruses and Opportunistic Infections, February, 2004Meeting Abstract
  • S Hopkins, A Khalid, G Courtney, F Mulcahy, C Bergin, Syphilis treatment outcomes in HIV infected and non-infected individuals, 11th Conference on Retroviruses and Opportunistic Infections, February, 2004Meeting Abstract
  • DAD study. (Includes Mulcahy F) , Cardio and cerebrovascular events and predicted rates of mycocardial infarction, 11th Conference on Retroviruses and Opportunistic Infections, February, 2004Meeting Abstract
  • M Hennessy, F Mulcahy, P Spiers, S Hospkins, P Hoggard, S Kewn, D Back, C Bergin, Differential effects of Combined Pegylated Interferon and Ribavirin Therapy? On intracellular Nucleotide Triphosphate levels in HIV/HCV coinfected patients: a potential mechanism for enhanced toxicity, 11th Conference on Retroviruses and Opportunistic Infections, February, 2004Meeting Abstract
  • F. Lyons, S. Coughlan, C. Byrne, S. Hopkins, Wm. Hall, C. Bergin and F. Mulcahy, Emergence of genotypic resistance in HIV-1 infected pregnant women taking highly antiretroviral therapy to reduce mother-to-child transmission of HIV-1, Poster 892, 11th Conference on Retroviruses and Opportunistic Infections, San Francisco, February, 2004Meeting Abstract
  • F.Lyons, E. Devitt, S. Hopkins, F. Mulcahy F, Sequential pregnancies in HIV infected women, BASHH/ASTDA Spring Meeting, Bath, UK, 19-21 May, 2004Meeting Abstract
  • Mulcahy F, The effectiveness of partner notification for gonococcal infection: A comparison between men who have sex with men ( MSM) and heterosexual males, BASHH/ASTDA Spring Meeting, Bath UK, 19-21 May, 2004Meeting Abstract
  • Mulcahy F, Co-infection with syphilis: natural history and management, 7th International Congress on Drug Therapy in HIV Infection, Glasgow, UK, 14-18 Nov, 2004Meeting Abstract
  • Holmes A, McCullagh L, Bergin C, Mulcahy F, Long term follow up of a cohort of antiretroviral experienced HIV-1 infected pateitns simplified to Trizivir, 7th International Congress on Drug Therapy in HIV Infection, Glasgow, UK, 14-18 Nov, 2004Meeting Abstract
  • Moriarty M, McCullagh L, Sabra K, Bergin C, Mulcahy F., A complete drug history should be sought, 7th International Congress on Drug Therapy in HIV Infection, Glasgow, UK, 14-18 Nov, 2004Meeting Abstract
  • Chew N, Brannigan E, Lynch R, Mulcahy F, Bergin C., HIV tuberculosis coninfection. Changing prevalence and impact on antiretroviral use, 7th International Congress on Drug Therapy in HIV Infection, Glasgow, UK, 14-18 Nov, 2004Meeting Abstract

Research Expertise

  • Title
    AIDS directed programme on HIV treatment.
    Summary
    i. Concorde: A double blind placebo controlled study to determine the efficacy of Zidovudine in reducing disease progression among patients with CDC Group II and III HIV infection, (Medical Research Council, UK). ii. Alpha: A study of the efficacy and safety of 2,3 DDI in patients with HIV infection who are intolerant to Zidovudine (Medical Research Council, UK). iii. Delta: A randomised double-blind trial to assess the efficacy and safety of combinations of AZT (Zidovudine 3-azido-3-deoxythymidine) DDI (Didanosine, 2,3-dideoxyinosine) and DDC (dideoxycytidine) in patients with Human Immune Virus (HIV) infection.
    Funding Agency
    Co-grant holder of Medical Research Council (MRC)
    Date From
    1988
    Date To
    1998
  • Title
    Collaborative Multicentre Study on HIV infection in women.
    Summary
    Co-grant holder investigator of MRC Collaborative Multicentre Study on HIV infection in women.
    Funding Agency
    MRC
    Date From
    1994
    Date To
    1997
  • Title
    "An evaluation of the benefits and risks of Isoniazid Chemoprophylaxis for Tuberculosis in individuals with HIV infection, considered to be at increased risk of developing Tuberculosis".
    Summary
    Co-investigator of Medical Research Council (MRC)
    Funding Agency
    MRC
    Date From
    1999
  • Title
    "An open randomised trial to evaluate different therapeutic strategies of combination therapy for HIV I infection"
    Summary
    Principal -investigator of INITIO Trial with Medical Research Council (MRC), London. .
    Funding Agency
    MRC
    Date From
    1999
    Date To
    2004
  • Title
    2NN Extended Follow up.
    Summary
    Principal investigator - 2NN Extended Follow up. The objective is to compare the virological, immunological and clinical efficacy of the different arms in the 2NN study in patients who were still using randomised treatment at the end of the 2NN study (week 48)
    Date From
    2004
    Date To
    to date
  • Title
    Methadone/Neviripine study
    Summary
    Principle Investigator - An open label pharmacokinetic study to evaluate the interaction between Nevirapine and Methadone in HIV-1 infected, opoid-dependent adults on stable methadone maintenance therapy. Boehringer
    Date From
    2002
    Date To
    2003
  • Title
    Study on Molecular Epidemiology of HIV infection
    Summary
    Co-investigator of MRC Study on Molecular Epidemiology of HIV infection
    Funding Agency
    MRC
    Date From
    1993
    Date To
    1997
  • Title
    OD + Methadone (Gilead) An open label multicentre study
    Summary
    Principal investigator - OD + Methadone (Gilead) An open label multicentre study to assess efficacy, tolerability and adherence of a once daily taken ART containing Tenofovir 300mgs in combination with the best suitable once daily regimen being 2 NRTI's or 1 NRTI plus 1 PI or 1 NRTI plus 1 NNRTI in HIV infected IVDU patients with opiate substitution being either ART naïve or with suppressed viral load and without a history of virological failure.
    Date From
    2004
    Date To
    to date
  • Title
    Resist roll-over (Boehringer Ingelheim) Access to Tipranavir for patients who were randomised to the PI?RTV arm with a lack of virologic response or confirmed virologic failure after eight weeks of treatment.
    Summary
    Principal investigator
    Date From
    2003
    Date To
    to date
  • Title
    Resist (Boehringer Ingelheim) Randomised evaluation of strategic intervention in multi drug resistant patients with Tipranavir.
    Summary
    Principal investigator
    Date From
    2003
    Date To
    to date
  • Title
    COLATE (Continue On Lamividine Treatment in Europe)
    Summary
    Principal investigator of COLATE (Continue On Lamividine Treatment in Europe), Copenhagen HIV Programme (CHIP).
    Date From
    1999
    Date To
    2003
  • Title
    ESPIRIT (MRC/HIH) A phase III open label, randomised trial to compare the effects of subcutaneous recombinant interleukin 2 (SC rIL -2) on disease progression in patients who are receiving ART.
    Summary
    Principal investigator
    Date From
    2001
    Date To
    to date